

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## **1. NAME OF THE MEDICINAL PRODUCT**

Galafold 123 mg hard capsules

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat.

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Hard capsule.

Size 2 hard capsule (6.4x18.0 mm) with an opaque blue cap and opaque white body with “A1001” printed in black, containing white to pale brown powder.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Galafold is indicated for long-term treatment of adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease ( $\alpha$ -galactosidase A deficiency) and who have an amenable mutation (see the tables in section 5.1).

### **4.2 Posology and method of administration**

Treatment with Galafold should be initiated and supervised by specialist physicians experienced in the diagnosis and treatment of Fabry disease. Galafold is not intended for concomitant use with enzyme replacement therapy (see section 4.4).

#### Posology

The recommended dosage regimen is 123 mg migalastat (1 capsule) taken once every other day at the same time of the day.

#### Missed dose

Galafold should not be taken on 2 consecutive days. If a dose is missed entirely for the day, the patient should take the missed dose of Galafold only if it is within 12 hours of the normal time the dose is taken. If more than 12 hours has passed the patient should resume taking Galafold at the next planned dosing day and time according to the every other day dosing schedule.

## Special populations

### Elderly population

No dosage adjustment is required based on age (see section 5.2).

### Renal impairment

Galafold is not recommended for use in patients with Fabry disease who have estimated GFR less than 30 mL/min/1.73 m<sup>2</sup> (see section 5.2).

### Hepatic impairment

No dosage adjustment of Galafold is required in patients with hepatic impairment (see section 5.2).

### Paediatric population

*Adolescents aged  $\geq 12$  to  $< 18$  years and weighing  $\geq 45$  kg*

123 mg migalastat (1 capsule) taken once every other day at the same time of the day (see section 5.2).

*Children  $< 12$  years*

The safety and efficacy of Galafold in children aged less than 12 years have not yet been established. No data are available.

### Method of administration

For oral use. Galafold exposure is decreased by approximately 40% when taken with food and therefore food should not be consumed at least 2 hours before and 2 hours after taking Galafold to give a minimum 4 hours fast. Clear liquids, including carbonated drinks, can be consumed during this period. Galafold should be taken every other day at the same time of day to ensure optimal benefits to the patient.

Capsules must be swallowed whole. The capsules must not be cut, crushed, or chewed.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

## **4.4 Special warnings and precautions for use**

It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on or switched to migalastat. In case of meaningful clinical deterioration, further clinical evaluation or discontinuation of treatment with Galafold should be considered.

Galafold is not indicated for use in patients with non-amenable mutations (see section 5.1).

No reduction in proteinuria was observed in patients treated with Galafold. Galafold is not recommended for use in patients with severe renal insufficiency, defined as estimated GFR less than 30 mL/min/1.73m<sup>2</sup> (see section 5.2).

Limited data suggest that co-administration of a single dose of migalastat and a standard enzyme replacement therapy infusion results in an increased exposure to agalsidase of up to 5-fold. This study also indicated that agalsidase has no effect on the pharmacokinetics of migalastat. Galafold is not intended for concomitant use with enzyme replacement therapy.

### Paediatric population

123 mg migalastat capsules are not for children ( $\geq 12$  years) weighing less than 45 kg, (see section 5.2).

## **4.5 Interaction with other medicinal products and other forms of interaction**

Based upon *in vitro* data, migalastat is not an inducer of CYP1A2, 2B6, or 3A4. Furthermore, migalastat is not an inhibitor or a substrate of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, or 3A4/5. Migalastat is not a substrate for MDR1 or BCRP, nor is it an inhibitor of BCRP, MDR1, or BSEP human efflux transporters. In addition, migalastat is not a substrate for MATE1, MATE2-K, OAT1, OAT3, or OCT2, nor is it an inhibitor of OATP1B1, OATP1B3, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K human uptake transporters.

## **4.6 Fertility, pregnancy and lactation**

### Women of childbearing potential/Contraception in males and females

Galafold is not recommended in women of childbearing potential not using contraception.

### Pregnancy

There are limited data from the use of Galafold in pregnant women. In rabbits, developmental toxicity was observed only at maternally toxic doses (see section 5.3). Galafold is not recommended during pregnancy.

### Breast-feeding

It is not known whether Galafold is secreted in human milk. However, migalastat has been shown to be expressed in the milk of lactating rats. Accordingly, a risk of migalastat exposure to the breast-feeding infant cannot be excluded. A decision must be made whether to discontinue breast-feeding or to discontinue Galafold, taking into account the benefit of breast-feeding for the child relative to the benefit of therapy for the mother.

### Fertility

The effects of Galafold on fertility in humans have not been studied. Transient and fully reversible infertility in male rats was associated with migalastat treatment at all doses assessed. Complete reversibility was seen after 4 weeks off-dose. Similar findings have been noted pre-clinically following treatment with other iminosugars (see section 5.3). Migalastat did not affect fertility in female rats.

## **4.7 Effects on ability to drive and use machines**

Galafold has no or negligible influence on the ability to drive and use machines.

## **4.8 Undesirable effects**

### Summary of the safety profile

The most common adverse reaction was headache, which was experienced by approximately 10% of patients who received Galafold.

### Tabulated list of adverse reactions

Frequencies are defined as: very common ( $\geq 1/10$ ), common ( $\geq 1/100$  to  $< 1/10$ ), uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), rare ( $\geq 1/10,000$  to  $< 1/1,000$ ), very rare ( $< 1/10,000$ ) and not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing frequency within each System Organ Class.

**Table 1: Adverse reactions with Galafold**

<b>System organ class</b>	<b>Very common</b>	<b>Common</b>
Psychiatric disorders		Depression
Nervous system disorders	Headache	Paraesthesia Dizziness Hypoaesthesia
Ear and labyrinth disorders		Vertigo
Cardiac disorders		Palpitations
Respiratory, thoracic, and mediastinal disorders		Dyspnoea Epistaxis
Gastrointestinal disorders		Diarrhoea Nausea Abdominal pain Constipation Dry mouth Defaecation urgency Dyspepsia
Skin and subcutaneous tissue disorders		Rash Pruritus
Musculoskeletal and connective tissue disorders		Muscle spasms Myalgia Torticollis Pain in extremity
Renal and urinary disorders		Proteinuria
General disorders and administration site conditions		Fatigue Pain
Investigations		Blood creatine phosphokinase increased Weight increased

### Adolescent population

The safety assessment in 21 adolescents (12 to  $< 18$  years of age and weighing  $\geq 45$  kg) is based on 1-year safety data from the open label AT1001-020 trial in which subjects received the same dosage regimen as adults (see section 5.2). No age-specific differences in adverse reactions were observed between adolescent and adult subjects. The frequency, type and severity of adverse reactions in adolescents are expected to be the same as in adults based on these data.

## Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

### **4.9 Overdose**

In case of overdose, general medical care is recommended. Headache and dizziness were the most common adverse reactions reported at doses of Galafold of up to 1250 mg and 2000 mg, respectively.

## **5. PHARMACOLOGICAL PROPERTIES**

### **5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Other alimentary tract and metabolism products, various alimentary tract and metabolism products, ATC code: A16AX14

Fabry disease is a progressive X-linked lysosomal storage disorder which affects males and females. Fabry disease-causing mutations in the *GLA* gene result in a deficiency of the lysosomal enzyme  $\alpha$ -galactosidase A ( $\alpha$ -Gal A) that is required for glycosphingolipid substrate (e.g., GL-3, lyso-Gb<sub>3</sub>) metabolism. Reduced  $\alpha$ -Gal A activity is, therefore, associated with the progressive accumulation of substrate in vulnerable organs and tissues, which leads to the morbidity and mortality associated with Fabry disease.

#### Mechanism of action

Certain *GLA* mutations can result in the production of abnormally folded and unstable mutant forms of  $\alpha$ -Gal A. Migalastat is a pharmacological chaperone that is designed to selectively and reversibly bind with high affinity to the active sites of certain mutant forms of  $\alpha$ -Gal A, the genotypes of which are referred to as amenable mutations. Migalastat binding stabilises these mutant forms of  $\alpha$ -Gal A in the endoplasmic reticulum and facilitates their proper trafficking to lysosomes. Once in lysosomes dissociation of migalastat restores  $\alpha$ -Gal A activity, leading to the catabolism of GL-3 and related substrates.

The *GLA* mutations amenable to treatment with Galafold are listed in Table 2 below. The *GLA* mutations are also accessible by health care providers at [www.galafoldamenabilitytable.com](http://www.galafoldamenabilitytable.com).

The nucleotide changes listed represent potential DNA sequence changes that result in the amino acid mutation. The amino acid mutation (protein sequence change) is most relevant when determining amenability. If a double mutation is present on the same chromosome (males and females), that patient is amenable if the double mutation is present in one entry in Table 2 (e.g., D55V/Q57L). If a double mutation is present on different chromosomes (only in females) that patient is amenable if either one of the individual mutations is present in Table 2.

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.7C>G	c.C7G	L3V
c.8T>C	c.T8C	L3P
c.[11G>T; 620A>C]	c.G11T/A620C	R4M/Y207S
c.13A>G	c.A13G	N5D
c.15C>G	c.C15G	N5K
c.16C>A	c.C16A	P6T
c.16C>T	c.C16T	P6S
c.17C>A	c.C17A	P6Q
c.17C>G	c.C17G	P6R
c.17C>T	c.C17T	P6L
c.19G>A	c.G19A	E7K
c.20A>T	c.A20T	E7V
c.21A>T	c.A21T	E7D
c.22C>A	c.C22A	L8I
c.23T>A	c.T23A	L8Q
c.23T>C	c.T23C	L8P
c.25C>T	c.C25T	H9Y
c.26A>G	c.A26G	H9R
c.26A>T	c.A26T	H9L
c.27T>A	c.T27A	H9Q
c.28C>A	c.C28A	L10M
c.28C>G	c.C28G	L10V
c.29T>A	c.T29A	L10Q
c.29T>C	c.T29C	L10P
c.29T>G	c.T29G	L10R
c.31G>A	c.G31A	G11S
c.31G>C	c.G31C	G11R
c.31G>T	c.G31T	G11C
c.32G>A	c.G32A	G11D
c.32G>T	c.G32T	G11V
c.34T>A	c.T34A	C12S
c.34T>C	c.T34C	C12R
c.34T>G	c.T34G	C12G
c.35G>A	c.G35A	C12Y
c.37G>A	c.G37A	A13T
c.37G>C	c.G37C	A13P
c.38C>A	c.C38A	A13E
c.38C>G	c.C38G	A13G
c.40C>G	c.C40G	L14V
c.40C>T	c.C40T	L14F
c.41T>A	c.T41A	L14H
c.43G>A	c.G43A	A15T
c.44C>G	c.C44G	A15G
c.49C>A	c.C49A	R17S
c.49C>G	c.C49G	R17G
c.49C>T	c.C49T	R17C
c.50G>A	c.G50A	R17H
c.50G>C	c.G50C	R17P

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.52T>A	c.T52A	F18I
c.53T>G	c.T53G	F18C
c.54C>G	c.C54G	F18L
c.58G>C	c.G58C	A20P
c.59C>A	c.C59A	A20D
c.59C>G	c.C59G	A20G
c.62T>A	c.T62A	L21H
c.64G>A	c.G64A	V22I
c.64G>C	c.G64C	V22L
c.64G>T	c.G64T	V22F
c.65T>C	c.T65C	V22A
c.65T>G	c.T65G	V22G
c.67T>A	c.T67A	S23T
c.67T>C	c.T67C	S23P
c.[70T>A; 1255A>G]	c.T70A/A1255G	W24R/N419D
c.70T>C or c.70T>A	c.T70C or c.T70A	W24R
c.70T>G	c.T70G	W24G
c.71G>C	c.G71C	W24S
c.72G>C or c.72G>T	c.G72C or c.G72T	W24C
c.73G>C	c.G73C	D25H
c.77T>A	c.T77A	I26N
c.79C>A	c.C79A	P27T
c.79C>G	c.C79G	P27A
c.79C>T	c.C79T	P27S
c.80C>T	c.C80T	P27L
c.82G>C	c.G82C	G28R
c.82G>T	c.G82T	G28W
c.83G>A	c.G83A	G28E
c.85G>C	c.G85C	A29P
c.86C>A	c.C86A	A29D
c.86C>G	c.C86G	A29G
c.86C>T	c.C86T	A29V
c.88A>G	c.A88G	R30G
c.94C>A	c.C94A	L32M
c.94C>G	c.C94G	L32V
c.95T>A	c.T95A	L32Q
c.95T>C	c.T95C	L32P
c.95T>G	c.T95G	L32R
c.97G>C	c.G97C	D33H
c.97G>T	c.G97T	D33Y
c.98A>C	c.A98C	D33A
c.98A>G	c.A98G	D33G
c.98A>T	c.A98T	D33V
c.99C>G	c.C99G	D33E
c.100A>C	c.A100C	N34H
c.100A>G	c.A100G	N34D
c.101A>C	c.A101C	N34T
c.101A>G	c.A101G	N34S
c.102T>G or c.102T>A	c.T102G or c.T102A	N34K
c.103G>C or c.103G>A	c.G103C or c.G103A	G35R



**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.104G>A	c.G104A	G35E
c.104G>C	c.G104C	G35A
c.104G>T	c.G104T	G35V
c.106T>A	c.T106A	L36M
c.106T>G	c.T106G	L36V
c.107T>C	c.T107C	L36S
c.107T>G	c.T107G	L36W
c.108G>C or c.108G>T	c.G108C or c.G108T	L36F
c.109G>A	c.G109A	A37T
c.109G>T	c.G109T	A37S
c.110C>A	c.C110A	A37E
c.110C>G	c.C110G	A37G
c.110C>T	c.C110T	A37V
c.112A>G	c.A112G	R38G
c.112A>T	c.A112T	R38W
c.113G>T	c.G113T	R38M
c.114G>C	c.G114C	R38S
c.115A>G	c.A115G	T39A
c.115A>T	c.A115T	T39S
c.116C>A	c.C116A	T39K
c.116C>G	c.C116G	T39R
c.116C>T	c.C116T	T39M
c.121A>G	c.A121G	T41A
c.122C>A	c.C122A	T41N
c.122C>G	c.C122G	T41S
c.122C>T	c.C122T	T41I
c.124A>C or c.124A>T	c.A124C or c.A124T	M42L
c.124A>G	c.A124G	M42V
c.125T>A	c.T125A	M42K
c.125T>C	c.T125C	M42T
c.125T>G	c.T125G	M42R
c.126G>A or c.126G>C or c.126G>T	c.G126A or c.G126C or c.G126T	M42I
c.128G>C	c.G128C	G43A
c.133C>A	c.C133A	L45M
c.133C>G	c.C133G	L45V
c.136C>A	c.C136A	H46N
c.136C>G	c.C136G	H46D
c.137A>C	c.A137C	H46P
c.138C>G	c.C138G	H46Q
c.142G>C	c.G142C	E48Q
c.143A>C	c.A143C	E48A
c.149T>A	c.T149A	F50Y
c.151A>G	c.A151G	M51V
c.152T>A	c.T152A	M51K
c.152T>C	c.T152C	M51T
c.152T>G	c.T152G	M51R
c.153G>A or c.153G>T or c.153G>C	c.G153A or c.G153T or c.G153C	M51I
c.157A>C	c.A157C	N53H

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.[157A>C; 158A>T]	c.A157C/A158T	N53L
c.157A>G	c.A157G	N53D
c.157A>T	c.A157T	N53Y
c.158A>C	c.A158C	N53T
c.158A>G	c.A158G	N53S
c.158A>T	c.A158T	N53I
c.159C>G or c.159C>A	c.C159G or c.C159A	N53K
c.160C>G	c.C160G	L54V
c.160C>T	c.C160T	L54F
c.161T>A	c.T161A	L54H
c.161T>C	c.T161C	L54P
c.161T>G	c.T161G	L54R
c.163G>C	c.G163C	D55H
c.163G>T	c.G163T	D55Y
c.164A>C	c.A164C	D55A
c.164A>G	c.A164G	D55G
c.164A>T	c.A164T	D55V
c.[164A>T; 170A>T]	c.A164T/A170T	D55V/Q57L
c.165C>G	c.C165G	D55E
c.167G>A	c.G167A	C56Y
c.167G>T	c.G167T	C56F
c.168C>G	c.C168G	C56W
c.170A>G	c.A170G	Q57R
c.170A>T	c.A170T	Q57L
c.172G>A	c.G172A	E58K
c.175G>A	c.G175A	E59K
c.175G>C	c.G175C	E59Q
c.176A>C	c.A176C	E59A
c.176A>G	c.A176G	E59G
c.176A>T	c.A176T	E59V
c.177G>C	c.G177C	E59D
c.178C>A	c.C178A	P60T
c.178C>G	c.C178G	P60A
c.178C>T	c.C178T	P60S
c.179C>A	c.C179A	P60Q
c.179C>G	c.C179G	P60R
c.179C>T	c.C179T	P60L
c.182A>T	c.A182T	D61V
c.183T>A	c.T183A	D61E
c.184_185insTAG	c.184_185insTAG	S62delinsLA
c.184T>C	c.T184C	S62P
c.184T>G	c.T184G	S62A
c.185C>A	c.C185A	S62Y
c.185C>G	c.C185G	S62C
c.185C>T	c.C185T	S62F
c.190A>C	c.A190C	I64L
c.190A>G	c.A190G	I64V
c.193A>G	c.A193G	S65G
c.193A>T	c.A193T	S65C
c.195T>A	c.T195A	S65R

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.196G>A	c.G196A	E66K
c.197A>G	c.A197G	E66G
c.197A>T	c.A197T	E66V
c.198G>C	c.G198C	E66D
c.199A>C	c.A199C	K67Q
c.199A>G	c.A199G	K67E
c.200A>C	c.A200C	K67T
c.200A>T	c.A200T	K67M
c.201G>C	c.G201C	K67N
c.202C>A	c.C202A	L68I
c.205T>A	c.T205A	F69I
c.206T>A	c.T206A	F69Y
c.207C>A or c.207C>G	c.C207A or c.C207G	F69L
c.208A>T	c.A208T	M70L
c.209T>A	c.T209A	M70K
c.209T>G	c.T209G	M70R
c.210G>C	c.G210C	M70I
c.211G>C	c.G211C	E71Q
c.212A>C	c.A212C	E71A
c.212A>G	c.A212G	E71G
c.212A>T	c.A212T	E71V
c.213G>C	c.G213C	E71D
c.214A>G	c.A214G	M72V
c.214A>T	c.A214T	M72L
c.215T>C	c.T215C	M72T
c.216G>A or c.216G>T or c.216G>C	c.G216A or c.G216T or c.G216C	M72I
c.217G>A	c.G217A	A73T
c.217G>T	c.G217T	A73S
c.218C>T	c.C218T	A73V
c.[218C>T; 525C>G]	c.C218T/C525G	A73V/D175E
c.220G>A	c.G220A	E74K
c.221A>G	c.A221G	E74G
c.221A>T	c.A221T	E74V
c.222G>C	c.G222C	E74D
c.223C>T	c.C223T	L75F
c.224T>C	c.T224C	L75P
c.226A>G	c.A226G	M76V
c.227T>C	c.T227C	M76T
c.229G>A	c.G229A	V77I
c.229G>C	c.G229C	V77L
c.232T>C	c.T232C	S78P
c.233C>T	c.C233T	S78L
c.235G>A	c.G235A	E79K
c.235G>C	c.G235C	E79Q
c.236A>C	c.A236C	E79A
c.236A>G	c.A236G	E79G
c.236A>T	c.A236T	E79V
c.237A>T	c.A237T	E79D
c.238G>A	c.G238A	G80S

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.238G>T	c.G238T	G80C
c.239G>A	c.G239A	G80D
c.239G>C	c.G239C	G80A
c.239G>T	c.G239T	G80V
c.242G>T	c.G242T	W81L
c.244A>G	c.A244G	K82E
c.245A>C	c.A245C	K82T
c.245A>G	c.A245G	K82R
c.245A>T	c.A245T	K82M
c.246G>C	c.G246C	K82N
c.247G>A	c.G247A	D83N
c.248A>C	c.A248C	D83A
c.248A>G	c.A248G	D83G
c.248A>T	c.A248T	D83V
c.249T>A	c.T249A	D83E
c.250G>A	c.G250A	A84T
c.250G>C	c.G250C	A84P
c.250G>T	c.G250T	A84S
c.251C>A	c.C251A	A84E
c.251C>G	c.C251G	A84G
c.251C>T	c.C251T	A84V
c.253G>A	c.G253A	G85S
c.[253G>A; 254G>A]	c.G253A/G254A	G85N
c.[253G>A; 254G>T; 255T>G]	c.G253A/G254T/T255G	G85M
c.253G>C	c.G253C	G85R
c.253G>T	c.G253T	G85C
c.254G>A	c.G254A	G85D
c.254G>C	c.G254C	G85A
c.257A>T	c.A257T	Y86F
c.260A>G	c.A260G	E87G
c.261G>C or c.261G>T	c.G261C or c.G261T	E87D
c.262T>A	c.T262A	Y88N
c.262T>C	c.T262C	Y88H
c.263A>C	c.A263C	Y88S
c.263A>G	c.A263G	Y88C
c.265C>G	c.C265G	L89V
c.265C>T	c.C265T	L89F
c.271A>C	c.A271C	I91L
c.271A>T	c.A271T	I91F
c.272T>C	c.T272C	I91T
c.272T>G	c.T272G	I91S
c.273T>G	c.T273G	I91M
c.286A>G	c.A286G	M96V
c.286A>T	c.A286T	M96L
c.287T>C	c.T287C	M96T
c.288G>A or c.288G>T or c.288G>C	c.G288A or c.G288T or c.G288C	M96I
c.289G>A	c.G289A	A97T
c.289G>C	c.G289C	A97P
c.289G>T	c.G289T	A97S

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.290C>A	c.C290A	A97D
c.290C>T	c.C290T	A97V
c.293C>A	c.C293A	P98H
c.293C>G	c.C293G	P98R
c.293C>T	c.C293T	P98L
c.295C>G	c.C295G	Q99E
c.296A>C	c.A296C	Q99P
c.296A>G	c.A296G	Q99R
c.296A>T	c.A296T	Q99L
c.301G>C	c.G301C	D101H
c.302A>C	c.A302C	D101A
c.302A>G	c.A302G	D101G
c.302A>T	c.A302T	D101V
c.303T>A	c.T303A	D101E
c.304T>A	c.T304A	S102T
c.304T>C	c.T304C	S102P
c.304T>G	c.T304G	S102A
c.305C>T	c.C305T	S102L
c.310G>A	c.G310A	G104S
c.311G>A	c.G311A	G104D
c.311G>C	c.G311C	G104A
c.311G>T	c.G311T	G104V
c.313A>G	c.A313G	R105G
c.314G>A	c.G314A	R105K
c.314G>C	c.G314C	R105T
c.314G>T	c.G314T	R105I
c.316C>A	c.C316A	L106I
c.316C>G	c.C316G	L106V
c.316C>T	c.C316T	L106F
c.317T>A	c.T317A	L106H
c.317T>C	c.T317C	L106P
c.319C>A	c.C319A	Q107K
c.319C>G	c.C319G	Q107E
c.320A>G	c.A320G	Q107R
c.321G>C	c.G321C	Q107H
c.322G>A	c.G322A	A108T
c.323C>A	c.C323A	A108E
c.323C>T	c.C323T	A108V
c.325G>A	c.G325A	D109N
c.325G>C	c.G325C	D109H
c.325G>T	c.G325T	D109Y
c.326A>C	c.A326C	D109A
c.326A>G	c.A326G	D109G
c.327C>G	c.C327G	D109E
c.328C>A	c.C328A	P110T
c.334C>G	c.C334G	R112G
c.335G>A	c.G335A	R112H
c.335G>T	c.G335T	R112L
c.337T>A	c.T337A	F113I

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.337T>C or c.339T>A or c.339T>G	c.T337C or c.T339A or c.T339G	F113L
c.337T>G	c.T337G	F113V
c.338T>A	c.T338A	F113Y
c.341C>T	c.C341T	P114L
c.343C>A	c.C343A	H115N
c.343C>G	c.C343G	H115D
c.346G>C	c.G346C	G116R
c.350T>C	c.T350C	I117T
c.351T>G	c.T351G	I117M
c.352C>T	c.C352T	R118C
c.361G>A	c.G361A	A121T
c.362C>T	c.C362T	A121V
c.367T>A	c.T367A	Y123N
c.367T>G	c.T367G	Y123D
c.368A>C	c.A368C	Y123S
c.368A>G	c.A368G	Y123C
c.368A>T	c.A368T	Y123F
c.370G>A	c.G370A	V124I
c.371T>G	c.T371G	V124G
c.373C>A	c.C373A	H125N
c.373C>G	c.C373G	H125D
c.373C>T	c.C373T	H125Y
c.374A>G	c.A374G	H125R
c.374A>T	c.A374T	H125L
c.376A>G	c.A376G	S126G
c.376A>T	c.A376T	S126C
c.377G>T	c.G377T	S126I
c.379A>G	c.A379G	K127E
c.383G>A	c.G383A	G128E
c.383G>C	c.G383C	G128A
c.385C>G	c.C385G	L129V
c.388A>C	c.A388C	K130Q
c.389A>T	c.A389T	K130M
c.390G>C	c.G390C	K130N
c.391C>G	c.C391G	L131V
c.397A>C	c.A397C	I133L
c.397A>G	c.A397G	I133V
c.397A>T	c.A397T	I133F
c.398T>C	c.T398C	I133T
c.399T>G	c.T399G	I133M
c.[399T>G; 434T>C]	c.T399G/T434C	I133M/F145S
c.403G>A	c.G403A	A135T
c.403G>T	c.G403T	A135S
c.404C>A	c.C404A	A135E
c.404C>G	c.C404G	A135G
c.404C>T	c.C404T	A135V
c.406G>A	c.G406A	D136N
c.407A>C	c.A407C	D136A
c.407A>T	c.A407T	D136V

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.408T>A or c.408T>G	c.T408A or c.T408G	D136E
c.409G>A	c.G409A	V137I
c.409G>C	c.G409C	V137L
c.410T>A	c.T410A	V137D
c.410T>C	c.T410C	V137A
c.410T>G	c.T410G	V137G
c.413G>C	c.G413C	G138A
c.415A>C	c.A415C	N139H
c.415A>T	c.A415T	N139Y
c.416A>G	c.A416G	N139S
c.416A>T	c.A416T	N139I
c.417T>A	c.T417A	N139K
c.418A>C	c.A418C	K140Q
c.418A>G	c.A418G	K140E
c.419A>C	c.A419C	K140T
c.419A>G	c.A419G	K140R
c.419A>T	c.A419T	K140I
c.420A>T	c.A420T	K140N
c.421A>T	c.A421T	T141S
c.427G>A	c.G427A	A143T
c.428C>A	c.C428A	A143E
c.428C>G	c.C428G	A143G
c.428C>T	c.C428T	A143V
c.430G>A	c.G430A	G144S
c.430G>C	c.G430C	G144R
c.430G>T	c.G430T	G144C
c.431G>A	c.G431A	G144D
c.431G>C	c.G431C	G144A
c.431G>T	c.G431T	G144V
c.433T>G	c.T433G	F145V
c.434T>A	c.T434A	F145Y
c.434T>C	c.T434C	F145S
c.434T>G	c.T434G	F145C
c.435C>G	c.C435G	F145L
c.436C>A	c.C436A	P146T
c.436C>G	c.C436G	P146A
c.436C>T	c.C436T	P146S
c.437C>A	c.C437A	P146H
c.437C>G	c.C437G	P146R
c.437C>T	c.C437T	P146L
c.440G>C	c.G440C	G147A
c.442A>G	c.A442G	S148G
c.442A>T	c.A442T	S148C
c.443G>C	c.G443C	S148T
c.446T>G	c.T446G	F149C
c.449G>A	c.G449A	G150E
c.449G>T	c.G449T	G150V
c.451T>G	c.T451G	Y151D
c.452A>C	c.A452C	Y151S
c.452A>G	c.A452G	Y151C

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.454T>A	c.T454A	Y152N
c.454T>C	c.T454C	Y152H
c.454T>G	c.T454G	Y152D
c.455A>C	c.A455C	Y152S
c.455A>G	c.A455G	Y152C
c.455A>T	c.A455T	Y152F
c.457G>A	c.G457A	D153N
c.457G>C	c.G457C	D153H
c.457G>T	c.G457T	D153Y
c.458A>C	c.A458C	D153A
c.458A>T	c.A458T	D153V
c.465T>A or c.465T>G	c.T465A or c.T465G	D155E
c.466G>A	c.G466A	A156T
c.466G>T	c.G466T	A156S
c.467C>G	c.C467G	A156G
c.467C>T	c.C467T	A156V
c.469C>A	c.C469A	Q157K
c.469C>G	c.C469G	Q157E
c.470A>C	c.A470C	Q157P
c.470A>T	c.A470T	Q157L
c.471G>C or c.471G>T	c.G471C or c.G471T	Q157H
c.472A>G	c.A472G	T158A
c.472A>T	c.A472T	T158S
c.473C>A	c.C473A	T158N
c.473C>T	c.C473T	T158I
c.475T>A	c.T475A	F159I
c.475T>G	c.T475G	F159V
c.476T>A	c.T476A	F159Y
c.476T>G	c.T476G	F159C
c.477T>A	c.T477A	F159L
c.478G>A	c.G478A	A160T
c.478G>T	c.G478T	A160S
c.479C>A	c.C479A	A160D
c.479C>G	c.C479G	A160G
c.479C>T	c.C479T	A160V
c.481G>A	c.G481A	D161N
c.481G>C	c.G481C	D161H
c.481G>T	c.G481T	D161Y
c.482A>T	c.A482T	D161V
c.484T>G	c.T484G	W162G
c.485G>C	c.G485C	W162S
c.490G>A	c.G490A	V164I
c.490G>T	c.G490T	V164L
c.491T>C	c.T491C	V164A
c.493G>A	c.G493A	D165N
c.493G>C	c.G493C	D165H
c.494A>C	c.A494C	D165A
c.494A>G	c.A494G	D165G
c.495T>A	c.T495A	D165E
c.496_497delinsTC	c.496_497delinsTC	L166S



**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.496C>A	c.C496A	L166M
c.496C>G	c.C496G	L166V
c.[496C>G; 497T>G]	c.C496G/T497G	L166G
c.497T>A	c.T497A	L166Q
c.499C>A	c.C499A	L167I
c.499C>G	c.C499G	L167V
c.505T>A	c.T505A	F169I
c.505T>G	c.T505G	F169V
c.506T>A	c.T506A	F169Y
c.506T>C	c.T506C	F169S
c.506T>G	c.T506G	F169C
c.507T>A	c.T507A	F169L
c.511G>A	c.G511A	G171S
c.512G>C	c.G512C	G171A
c.512G>T	c.G512T	G171V
c.517T>C	c.T517C	Y173H
c.518A>C	c.A518C	Y173S
c.518A>G	c.A518G	Y173C
c.518A>T	c.A518T	Y173F
c.520T>C	c.T520C	C174R
c.520T>G	c.T520G	C174G
c.523G>C	c.G523C	D175H
c.523G>T	c.G523T	D175Y
c.524A>G	c.A524G	D175G
c.524A>T	c.A524T	D175V
c.525C>G or c.525C>A	c.C525G or c.C525A	D175E
c.526A>T	c.A526T	S176C
c.528T>A	c.T528A	S176R
c.529T>A	c.T529A	L177M
c.529T>G	c.T529G	L177V
c.530T>C	c.T530C	L177S
c.530T>G	c.T530G	L177W
c.531G>C	c.G531C	L177F
c.532G>A	c.G532A	E178K
c.532G>C	c.G532C	E178Q
c.533A>C	c.A533C	E178A
c.533A>G	c.A533G	E178G
c.538T>A	c.T538A	L180M
c.538T>G	c.T538G	L180V
c.539T>C	c.T539C	L180S
c.539T>G	c.T539G	L180W
c.540G>C or c.540G>T	c.G540C or c.G540T	L180F
c.541G>A	c.G541A	A181T
c.541G>C	c.G541C	A181P
c.542C>T	c.C542T	A181V
c.544G>T	c.G544T	D182Y
c.545A>C	c.A545C	D182A
c.545A>G	c.A545G	D182G
c.545A>T	c.A545T	D182V
c.546T>A	c.T546A	D182E

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.548G>A	c.G548A	G183D
c.548G>C	c.G548C	G183A
c.550T>A	c.T550A	Y184N
c.550T>C	c.T550C	Y184H
c.551A>C	c.A551C	Y184S
c.551A>G	c.A551G	Y184C
c.551A>T	c.A551T	Y184F
c.553A>C	c.A553C	K185Q
c.553A>G	c.A553G	K185E
c.554A>C	c.A554C	K185T
c.554A>T	c.A554T	K185M
c.555G>C	c.G555C	K185N
c.556C>A	c.C556A	H186N
c.556C>G	c.C556G	H186D
c.556C>T	c.C556T	H186Y
c.557A>T	c.A557T	H186L
c.558C>G	c.C558G	H186Q
c.559_564dup	c.559_564dup	p.M187_S188dup
c.559A>T	c.A559T	M187L
c.559A>G	c.A559G	M187V
c.560T>C	c.T560C	M187T
c.561G>T or c.561G>A or c.561G>C	c.G561T or c.G561A or c.G561C	M187I
c.562T>A	c.T562A	S188T
c.562T>C	c.T562C	S188P
c.562T>G	c.T562G	S188A
c.563C>A	c.C563A	S188Y
c.563C>G	c.C563G	S188C
c.563C>T	c.C563T	S188F
c.565T>G	c.T565G	L189V
c.566T>C	c.T566C	L189S
c.567G>C or c.567G>T	c.G567C or c.G567T	L189F
c.568G>A	c.G568A	A190T
c.568G>T	c.G568T	A190S
c.569C>A	c.C569A	A190D
c.569C>G	c.C569G	A190G
c.569C>T	c.C569T	A190V
c.571C>A	c.C571A	L191M
c.571C>G	c.C571G	L191V
c.572T>A	c.T572A	L191Q
c.574A>C	c.A574C	N192H
c.574A>G	c.A574G	N192D
c.575A>C	c.A575C	N192T
c.575A>G	c.A575G	N192S
c.576T>A	c.T576A	N192K
c.577A>G	c.A577G	R193G
c.577A>T	c.A577T	R193W
c.578G>C	c.G578C	R193T
c.578G>T	c.G578T	R193M
c.580A>C	c.A580C	T194P

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.580A>G	c.A580G	T194A
c.580A>T or c.581C>G	c.A580T or c.C581G	T194S
c.581C>A	c.C581A	T194N
c.581C>T	c.C581T	T194I
c.583G>A	c.G583A	G195S
c.583G>C	c.G583C	G195R
c.583G>T	c.G583T	G195C
c.584G>T	c.G584T	G195V
c.586A>G	c.A586G	R196G
c.587G>A	c.G587A	R196K
c.587G>C	c.G587C	R196T
c.587G>T	c.G587T	R196I
c.589A>G	c.A589G	S197G
c.589A>T	c.A589T	S197C
c.590G>A	c.G590A	S197N
c.590G>C	c.G590C	S197T
c.590G>T	c.G590T	S197I
c.593T>C	c.T593C	I198T
c.593T>G	c.T593G	I198S
c.594T>G	c.T594G	I198M
c.595G>A	c.G595A	V199M
c.595G>C	c.G595C	V199L
c.596T>A	c.T596A	V199E
c.596T>C	c.T596C	V199A
c.596T>G	c.T596G	V199G
c.598T>A	c.T598A	Y200N
c.599A>C	c.A599C	Y200S
c.599A>G	c.A599G	Y200C
c.601T>A	c.T601A	S201T
c.601T>G	c.T601G	S201A
c.602C>A	c.C602A	S201Y
c.602C>G	c.C602G	S201C
c.602C>T	c.C602T	S201F
c.607G>C	c.G607C	E203Q
c.608A>C	c.A608C	E203A
c.608A>G	c.A608G	E203G
c.608A>T	c.A608T	E203V
c.609G>C or c.609G>T	c.G609C or c.G609T	E203D
c.610T>G	c.T610G	W204G
c.611G>C	c.G611C	W204S
c.611G>T	c.G611T	W204L
c.613C>A	c.C613A	P205T
c.613C>T	c.C613T	P205S
c.614C>T	c.C614T	P205L
c.616C>A	c.C616A	L206I
c.616C>G	c.C616G	L206V
c.616C>T	c.C616T	L206F
c.617T>A	c.T617A	L206H
c.617T>G	c.T617G	L206R
c.619T>C	c.T619C	Y207H

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.620A>C	c.A620C	Y207S
c.620A>T	c.A620T	Y207F
c.623T>A	c.T623A	M208K
c.623T>G	c.T623G	M208R
c.625T>A	c.T625A	W209R
c.625T>G	c.T625G	W209G
c.627G>C	c.G627C	W209C
c.628C>A	c.C628A	P210T
c.628C>T	c.C628T	P210S
c.629C>A	c.C629A	P210H
c.629C>T	c.C629T	P210L
c.631T>C	c.T631C	F211L
c.631T>G	c.T631G	F211V
c.632T>A	c.T632A	F211Y
c.632T>C	c.T632C	F211S
c.632T>G	c.T632G	F211C
c.635A>C	c.A635C	Q212P
c.636A>T	c.A636T	Q212H
c.637A>C	c.A637C	K213Q
c.637A>G	c.A637G	K213E
c.638A>G	c.A638G	K213R
c.638A>T	c.A638T	K213M
c.640C>A	c.C640A	P214T
c.640C>G	c.C640G	P214A
c.640C>T	c.C640T	P214S
c.641C>A	c.C641A	P214H
c.641C>G	c.C641G	P214R
c.641C>T	c.C641T	P214L
c.643A>C	c.A643C	N215H
c.643A>G	c.A643G	N215D
c.643A>T	c.A643T	N215Y
c.644A>C	c.A644C	N215T
c.644A>G	c.A644G	N215S
c.[644A>G; 937G>T]	c.A644G/G937T	N215S/D313Y
c.644A>T	c.A644T	N215I
c.645T>A	c.T645A	N215K
c.646T>A	c.T646A	Y216N
c.646T>C	c.T646C	Y216H
c.646T>G	c.T646G	Y216D
c.647A>C	c.A647C	Y216S
c.647A>G	c.A647G	Y216C
c.647A>T	c.A647T	Y216F
c.649A>C	c.A649C	T217P
c.649A>G	c.A649G	T217A
c.649A>T	c.A649T	T217S
c.650C>A	c.C650A	T217K
c.650C>G	c.C650G	T217R
c.650C>T	c.C650T	T217I
c.652G>A	c.G652A	E218K
c.652G>C	c.G652C	E218Q

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.653A>C	c.A653C	E218A
c.653A>G	c.A653G	E218G
c.653A>T	c.A653T	E218V
c.654A>T	c.A654T	E218D
c.655A>C	c.A655C	I219L
c.655A>T	c.A655T	I219F
c.656T>A	c.T656A	I219N
c.656T>C	c.T656C	I219T
c.656T>G	c.T656G	I219S
c.657C>G	c.C657G	I219M
c.659G>A	c.G659A	R220Q
c.659G>C	c.G659C	R220P
c.659G>T	c.G659T	R220L
c.661C>A	c.C661A	Q221K
c.661C>G	c.C661G	Q221E
c.662A>C	c.A662C	Q221P
c.662A>G	c.A662G	Q221R
c.662A>T	c.A662T	Q221L
c.663G>C	c.G663C	Q221H
c.664T>A	c.T664A	Y222N
c.664T>C	c.T664C	Y222H
c.664T>G	c.T664G	Y222D
c.665A>C	c.A665C	Y222S
c.665A>G	c.A665G	Y222C
c.670A>C	c.A670C	N224H
c.671A>C	c.A671C	N224T
c.671A>G	c.A671G	N224S
c.673C>G	c.C673G	H225D
c.679C>G	c.C679G	R227G
c.682A>C	c.A682C	N228H
c.682A>G	c.A682G	N228D
c.683A>C	c.A683C	N228T
c.683A>G	c.A683G	N228S
c.683A>T	c.A683T	N228I
c.685T>A	c.T685A	F229I
c.686T>A	c.T686A	F229Y
c.686T>C	c.T686C	F229S
c.687T>A or c.687T>G	c.T687A or c.T687G	F229L
c.688G>C	c.G688C	A230P
c.689C>A	c.C689A	A230D
c.689C>G	c.C689G	A230G
c.689C>T	c.C689T	A230V
c.694A>C	c.A694C	I232L
c.694A>G	c.A694G	I232V
c.695T>C	c.T695C	I232T
c.696T>G	c.T696G	I232M
c.698A>C	c.A698C	D233A
c.698A>G	c.A698G	D233G
c.698A>T	c.A698T	D233V
c.699T>A	c.T699A	D233E

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.703T>A	c.T703A	S235T
c.703T>G	c.T703G	S235A
c.710A>T	c.A710T	K237I
c.712A>G	c.A712G	S238G
c.712A>T	c.A712T	S238C
c.713G>A	c.G713A	S238N
c.713G>C	c.G713C	S238T
c.713G>T	c.G713T	S238I
c.715A>T	c.A715T	I239L
c.716T>C	c.T716C	I239T
c.717A>G	c.A717G	I239M
c.718A>G	c.A718G	K240E
c.719A>G	c.A719G	K240R
c.719A>T	c.A719T	K240M
c.720G>C or c.720G>T	c.G720C or c.G720T	K240N
c.721A>T	c.A721T	S241C
c.722G>C	c.G722C	S241T
c.722G>T	c.G722T	S241I
c.724A>C	c.A724C	I242L
c.724A>G	c.A724G	I242V
c.724A>T	c.A724T	I242F
c.725T>A	c.T725A	I242N
c.725T>C	c.T725C	I242T
c.725T>G	c.T725G	I242S
c.726C>G	c.C726G	I242M
c.727T>A	c.T727A	L243M
c.727T>G	c.T727G	L243V
c.728T>C	c.T728C	L243S
c.728T>G	c.T728G	L243W
c.729G>C or c.729G>T	c.G729C or c.G729T	L243F
c.730G>A	c.G730A	D244N
c.730G>C	c.G730C	D244H
c.730G>T	c.G730T	D244Y
c.731A>C	c.A731C	D244A
c.731A>G	c.A731G	D244G
c.731A>T	c.A731T	D244V
c.732C>G	c.C732G	D244E
c.733T>G	c.T733G	W245G
c.735G>C	c.G735C	W245C
c.736A>G	c.A736G	T246A
c.737C>A	c.C737A	T246K
c.737C>G	c.C737G	T246R
c.737C>T	c.C737T	T246I
c.739T>A	c.T739A	S247T
c.739T>G	c.T739G	S247A
c.740C>A	c.C740A	S247Y
c.740C>G	c.C740G	S247C
c.740C>T	c.C740T	S247F
c.742T>G	c.T742G	F248V
c.743T>A	c.T743A	F248Y

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.743T>G	c.T743G	F248C
c.744T>A	c.T744A	F248L
c.745A>C	c.A745C	N249H
c.745A>G	c.A745G	N249D
c.745A>T	c.A745T	N249Y
c.746A>C	c.A746C	N249T
c.746A>G	c.A746G	N249S
c.746A>T	c.A746T	N249I
c.747C>G or c.747C>A	c.C747G or c.C747A	N249K
c.748C>A	c.C748A	Q250K
c.748C>G	c.C748G	Q250E
c.749A>C	c.A749C	Q250P
c.749A>G	c.A749G	Q250R
c.749A>T	c.A749T	Q250L
c.750G>C	c.G750C	Q250H
c.751G>A	c.G751A	E251K
c.751G>C	c.G751C	E251Q
c.752A>G	c.A752G	E251G
c.752A>T	c.A752T	E251V
c.754A>G	c.A754G	R252G
c.757A>G	c.A757G	I253V
c.757A>T	c.A757T	I253F
c.758T>A	c.T758A	I253N
c.758T>C	c.T758C	I253T
c.758T>G	c.T758G	I253S
c.760-762delGTT or c.761-763del	c.760_762delGTT or c.761_763del	p.V254del
c.760G>T	c.G760T	V254F
c.761T>A	c.T761A	V254D
c.761T>C	c.T761C	V254A
c.761T>G	c.T761G	V254G
c.763G>A	c.G763A	D255N
c.763G>C	c.G763C	D255H
c.763G>T	c.G763T	D255Y
c.764A>C	c.A764C	D255A
c.764A>T	c.A764T	D255V
c.765T>A	c.T765A	D255E
c.766G>C	c.G766C	V256L
c.767T>A	c.T767A	V256D
c.767T>G	c.T767G	V256G
c.769G>A	c.G769A	A257T
c.769G>C	c.G769C	A257P
c.769G>T	c.G769T	A257S
c.770C>G	c.C770G	A257G
c.770C>T	c.C770T	A257V
c.772G>C or c.772G>A	c.G772C or c.G772A	G258R
c.773G>A	c.G773A	G258E
c.773G>T	c.G773T	G258V
c.775C>A	c.C775A	P259T
c.775C>G	c.C775G	P259A

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.775C>T	c.C775T	P259S
c.776C>A	c.C776A	P259Q
c.776C>G	c.C776G	P259R
c.776C>T	c.C776T	P259L
c.778G>T	c.G778T	G260W
c.779G>A	c.G779A	G260E
c.779G>C	c.G779C	G260A
c.781G>A	c.G781A	G261S
c.781G>C	c.G781C	G261R
c.781G>T	c.G781T	G261C
c.782G>C	c.G782C	G261A
c.787A>C	c.A787C	N263H
c.788A>C	c.A788C	N263T
c.788A>G	c.A788G	N263S
c.790G>A	c.G790A	D264N
c.790G>C	c.G790C	D264H
c.790G>T	c.G790T	D264Y
c.793C>G	c.C793G	P265A
c.794C>A	c.C794A	P265Q
c.794C>T	c.C794T	P265L
c.799A>G	c.A799G	M267V
c.799A>T	c.A799T	M267L
c.800T>C	c.T800C	M267T
c.802T>A	c.T802A	L268I
c.804A>T	c.A804T	L268F
c.805G>A	c.G805A	V269M
c.805G>C	c.G805C	V269L
c.806T>C	c.T806C	V269A
c.808A>C	c.A808C	I270L
c.808A>G	c.A808G	I270V
c.809T>C	c.T809C	I270T
c.809T>G	c.T809G	I270S
c.810T>G	c.T810G	I270M
c.811G>A	c.G811A	G271S
c.[811G>A; 937G>T]	c.G811A/G937T	G271S/D313Y
c.812G>A	c.G812A	G271D
c.812G>C	c.G812C	G271A
c.814A>G	c.A814G	N272D
c.818T>A	c.T818A	F273Y
c.823C>A	c.C823A	L275I
c.823C>G	c.C823G	L275V
c.827G>A	c.G827A	S276N
c.827G>C	c.G827C	S276T
c.829T>G	c.T829G	W277G
c.830G>T	c.G830T	W277L
c.831G>T or c.831G>C	c.G831T or c.G831C	W277C
c.832A>T	c.A832T	N278Y
c.833A>T	c.A833T	N278I
c.835C>G	c.C835G	Q279E
c.838C>A	c.C838A	Q280K



**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.839A>G	c.A839G	Q280R
c.839A>T	c.A839T	Q280L
c.840A>T or c.840A>C	c.A840T or c.A840C	Q280H
c.841G>C	c.G841C	V281L
c.842T>A	c.T842A	V281E
c.842T>C	c.T842C	V281A
c.842T>G	c.T842G	V281G
c.844A>G	c.A844G	T282A
c.844A>T	c.A844T	T282S
c.845C>T	c.C845T	T282I
c.847C>G	c.C847G	Q283E
c.848A>T	c.A848T	Q283L
c.849G>C	c.G849C	Q283H
c.850A>G	c.A850G	M284V
c.850A>T	c.A850T	M284L
c.851T>C	c.T851C	M284T
c.852G>C	c.G852C	M284I
c.853G>A	c.G853A	A285T
c.854C>G	c.C854G	A285G
c.854C>T	c.C854T	A285V
c.856C>G	c.C856G	L286V
c.856C>T	c.C856T	L286F
c.857T>A	c.T857A	L286H
c.860G>T	c.G860T	W287L
c.862G>C	c.G862C	A288P
c.862G>T	c.G862T	A288S
c.863C>G	c.C863G	A288G
c.863C>T	c.C863T	A288V
c.865A>C	c.A865C	I289L
c.865A>G	c.A865G	I289V
c.866T>C	c.T866C	I289T
c.866T>G	c.T866G	I289S
c.868A>C or c.868A>T	c.A868C or c.A868T	M290L
c.868A>G	c.A868G	M290V
c.869T>C	c.T869C	M290T
c.870G>A or c.870G>C or c.870G>T	c.G870A or c.G870C or c.G870T	M290I
c.871G>A	c.G871A	A291T
c.871G>T	c.G871T	A291S
c.872C>G	c.C872G	A291G
c.874G>T	c.G874T	A292S
c.875C>G	c.C875G	A292G
c.877C>A	c.C877A	P293T
c.880T>A	c.T880A	L294I
c.880T>G	c.T880G	L294V
c.881T>C	c.T881C	L294S
c.882A>T	c.A882T	L294F
c.883T>A	c.T883A	F295I
c.883T>G	c.T883G	F295V
c.884T>A	c.T884A	F295Y

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.884T>C	c.T884C	F295S
c.884T>G	c.T884G	F295C
c.886A>G	c.A886G	M296V
c.886A>T or c.886A>C	c.A886T or c.A886C	M296L
c.887T>C	c.T887C	M296T
c.888G>A or c.888G>T or c.888G>C	c.G888A or c.G888T or c.G888C	M296I
c.889T>A	c.T889A	S297T
c.892A>G	c.A892G	N298D
c.893A>C	c.A893C	N298T
c.893A>G	c.A893G	N298S
c.893A>T	c.A893T	N298I
c.895G>A	c.G895A	D299N
c.895G>C	c.G895C	D299H
c.897C>G or c.897C>A	c.C897G or c.C897A	D299E
c.898C>A	c.C898A	L300I
c.898C>G	c.C898G	L300V
c.898C>T	c.C898T	L300F
c.899T>C	c.T899C	L300P
c.901C>G	c.C901G	R301G
c.902G>A	c.G902A	R301Q
c.902G>C	c.G902C	R301P
c.902G>T	c.G902T	R301L
c.904C>A	c.C904A	H302N
c.904C>G	c.C904G	H302D
c.904C>T	c.C904T	H302Y
c.905A>T	c.A905T	H302L
c.907A>G	c.A907G	I303V
c.907A>T	c.A907T	I303F
c.908T>A	c.T908A	I303N
c.908T>C	c.T908C	I303T
c.908T>G	c.T908G	I303S
c.911G>A	c.G911A	S304N
c.911G>C	c.G911C	S304T
c.911G>T	c.G911T	S304I
c.916C>G	c.C916G	Q306E
c.917A>C	c.A917C	Q306P
c.917A>T	c.A917T	Q306L
c.919G>A	c.G919A	A307T
c.919G>C	c.G919C	A307P
c.919G>T	c.G919T	A307S
c.920C>A	c.C920A	A307D
c.920C>G	c.C920G	A307G
c.920C>T	c.C920T	A307V
c.922A>C	c.A922C	K308Q
c.922A>G	c.A922G	K308E
c.923A>G	c.A923G	K308R
c.923A>T	c.A923T	K308I
c.924A>T or c.924A>C	c.A924T or c.A924C	K308N
c.925G>A	c.G925A	A309T

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.925G>C	c.G925C	A309P
c.926C>A	c.C926A	A309D
c.926C>T	c.C926T	A309V
c.928C>A	c.C928A	L310I
c.928C>G	c.C928G	L310V
c.928C>T	c.C928T	L310F
c.931C>A	c.C931A	L311I
c.931C>G	c.C931G	L311V
c.934C>A	c.C934A	Q312K
c.934C>G	c.C934G	Q312E
c.935A>G	c.A935G	Q312R
c.935A>T	c.A935T	Q312L
c.936G>T or c.936G>C	c.G936T or c.G936C	Q312H
c.937G>T	c.G937T	D313Y
c.[937G>T; 1232G>A]	c.G937T/G1232A	D313Y/G411D
c.938A>G	c.A938G	D313G
c.938A>T	c.A938T	D313V
c.939T>A	c.T939A	D313E
c.940A>G	c.A940G	K314E
c.941A>C	c.A941C	K314T
c.941A>T	c.A941T	K314M
c.942G>C	c.G942C	K314N
c.943G>A	c.G943A	D315N
c.943G>C	c.G943C	D315H
c.943G>T	c.G943T	D315Y
c.944A>C	c.A944C	D315A
c.944A>G	c.A944G	D315G
c.944A>T	c.A944T	D315V
c.946G>A	c.G946A	V316I
c.946G>C	c.G946C	V316L
c.947T>C	c.T947C	V316A
c.947T>G	c.T947G	V316G
c.949A>C	c.A949C	I317L
c.949A>G	c.A949G	I317V
c.950T>C	c.T950C	I317T
c.951T>G	c.T951G	I317M
c.952G>A	c.G952A	A318T
c.952G>C	c.G952C	A318P
c.953C>A	c.C953A	A318D
c.953C>T	c.C953T	A318V
c.955A>T	c.A955T	I319F
c.956T>C	c.T956C	I319T
c.957C>G	c.C957G	I319M
c.958A>C	c.A958C	N320H
c.959A>C	c.A959C	N320T
c.959A>G	c.A959G	N320S
c.959A>T	c.A959T	N320I
c.961C>A	c.C961A	Q321K
c.962A>G	c.A962G	Q321R
c.962A>T	c.A962T	Q321L

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.963G>C or c.963G>T	c.G963C or c.G963T	Q321H
c.964G>A	c.G964A	D322N
c.964G>C	c.G964C	D322H
c.965A>C	c.A965C	D322A
c.965A>T	c.A965T	D322V
c.966C>A or c.966C>G	c.C966A or c.C966G	D322E
c.967C>A	c.C967A	P323T
c.968C>G	c.C968G	P323R
c.970T>G	c.T970G	L324V
c.971T>G	c.T971G	L324W
c.973G>A	c.G973A	G325S
c.973G>C	c.G973C	G325R
c.973G>T	c.G973T	G325C
c.974G>C	c.G974C	G325A
c.974G>T	c.G974T	G325V
c.976A>C	c.A976C	K326Q
c.976A>G	c.A976G	K326E
c.977A>C	c.A977C	K326T
c.977A>G	c.A977G	K326R
c.977A>T	c.A977T	K326M
c.978G>C or c.978G>T	c.G978C or c.G978T	K326N
c.979C>G	c.C979G	Q327E
c.980A>C	c.A980C	Q327P
c.980A>T	c.A980T	Q327L
c.981A>T	c.A981T	Q327H
c.983G>C	c.G983C	G328A
c.985T>A	c.T985A	Y329N
c.985T>C	c.T985C	Y329H
c.985T>G	c.T985G	Y329D
c.986A>G	c.A986G	Y329C
c.986A>T	c.A986T	Y329F
c.988C>A	c.C988A	Q330K
c.988C>G	c.C988G	Q330E
c.989A>C	c.A989C	Q330P
c.989A>G	c.A989G	Q330R
c.990G>C	c.G990C	Q330H
c.991C>G	c.C991G	L331V
c.992T>A	c.T992A	L331H
c.992T>C	c.T992C	L331P
c.992T>G	c.T992G	L331R
c.994A>G	c.A994G	R332G
c.995G>C	c.G995C	R332T
c.995G>T	c.G995T	R332I
c.996A>T	c.A996T	R332S
c.997C>G	c.C997G	Q333E
c.998A>C	c.A998C	Q333P
c.998A>T	c.A998T	Q333L
c.1000G>C	c.G1000C	G334R
c.1001G>A	c.G1001A	G334E
c.1001G>T	c.G1001T	G334V

**Table 2: Galafold (migalastat) amenability table**

<b>Nucleotide change</b>	<b>Nucleotide change</b>	<b>Protein sequence change</b>
c.1003G>T	c.G1003T	D335Y
c.1004A>C	c.A1004C	D335A
c.1004A>G	c.A1004G	D335G
c.1004A>T	c.A1004T	D335V
c.1005C>G	c.C1005G	D335E
c.1006A>G	c.A1006G	N336D
c.1006A>T	c.A1006T	N336Y
c.1007A>C	c.A1007C	N336T
c.1007A>G	c.A1007G	N336S
c.1007A>T	c.A1007T	N336I
c.1009T>G	c.T1009G	F337V
c.1010T>A	c.T1010A	F337Y
c.1010T>C	c.T1010C	F337S
c.1010T>G	c.T1010G	F337C
c.1011T>A	c.T1011A	F337L
c.1012G>A	c.G1012A	E338K
c.1013A>C	c.A1013C	E338A
c.1013A>G	c.A1013G	E338G
c.1013A>T	c.A1013T	E338V
c.1014A>T	c.A1014T	E338D
c.1015G>A	c.G1015A	V339M
c.1016T>A	c.T1016A	V339E
c.1016T>C	c.T1016C	V339A
c.1021G>C	c.G1021C	E341Q
c.1022A>C	c.A1022C	E341A
c.1027C>A	c.C1027A	P343T
c.1027C>G	c.C1027G	P343A
c.1027C>T	c.C1027T	P343S
c.1028C>T	c.C1028T	P343L
c.1030C>G	c.C1030G	L344V
c.1030C>T	c.C1030T	L344F
c.1031T>G	c.T1031G	L344R
c.1033T>C	c.T1033C	S345P
c.1036G>T	c.G1036T	G346C
c.1037G>A	c.G1037A	G346D
c.1037G>C	c.G1037C	G346A
c.1037G>T	c.G1037T	G346V
c.1039T>A	c.T1039A	L347I
c.1043C>A	c.C1043A	A348D
c.1046G>C	c.G1046C	W349S
c.1046G>T	c.G1046T	W349L
c.1047G>C	c.G1047C	W349C
c.1048G>A	c.G1048A	A350T
c.1048G>T	c.G1048T	A350S
c.1049C>G	c.C1049G	A350G
c.1049C>T	c.C1049T	A350V
c.1052T>A	c.T1052A	V351E
c.1052T>C	c.T1052C	V351A
c.1054G>A	c.G1054A	A352T
c.1054G>T	c.G1054T	A352S

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.1055C>G	c.C1055G	A352G
c.1055C>T	c.C1055T	A352V
c.1057A>T	c.A1057T	M353L
c.1058T>A	c.T1058A	M353K
c.1058T>C	c.T1058C	M353T
c.1061T>A	c.T1061A	I354K
c.1061T>G	c.T1061G	I354R
c.1063A>C	c.A1063C	N355H
c.1063A>G	c.A1063G	N355D
c.1063A>T	c.A1063T	N355Y
c.1064A>G	c.A1064G	N355S
c.1066C>G	c.C1066G	R356G
c.1066C>T	c.C1066T	R356W
c.1067G>A	c.G1067A	R356Q
c.1067G>C	c.G1067C	R356P
c.1067G>T	c.G1067T	R356L
c.1069C>G	c.C1069G	Q357E
c.1072G>C	c.G1072C	E358Q
c.1073A>C	c.A1073C	E358A
c.1073A>G	c.A1073G	E358G
c.1074G>T or c.1074G>C	c.G1074T or c.G1074C	E358D
c.1075A>C	c.A1075C	I359L
c.1075A>G	c.A1075G	I359V
c.1075A>T	c.A1075T	I359F
c.1076T>A	c.T1076A	I359N
c.1076T>C	c.T1076C	I359T
c.1076T>G	c.T1076G	I359S
c.1078G>A	c.G1078A	G360S
c.1078G>C	c.G1078C	G360R
c.1078G>T	c.G1078T	G360C
c.1079G>A	c.G1079A	G360D
c.1079G>C	c.G1079C	G360A
c.1082G>A	c.G1082A	G361E
c.1082G>C	c.G1082C	G361A
c.1084C>A	c.C1084A	P362T
c.1084C>G	c.C1084G	P362A
c.1084C>T	c.C1084T	P362S
c.1085C>A	c.C1085A	P362H
c.1085C>G	c.C1085G	P362R
c.1085C>T	c.C1085T	P362L
c.1087C>A	c.C1087A	R363S
c.1087C>G	c.C1087G	R363G
c.1087C>T	c.C1087T	R363C
c.1088G>A	c.G1088A	R363H
c.1088G>T	c.G1088T	R363L
c.1090T>C	c.T1090C	S364P
c.1091C>G	c.C1091G	S364C
c.1093T>A	c.T1093A	Y365N
c.1093T>G	c.T1093G	Y365D
c.1094A>C	c.A1094C	Y365S

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.1094A>T	c.A1094T	Y365F
c.1096A>C	c.A1096C	T366P
c.1096A>T	c.A1096T	T366S
c.1097C>A	c.C1097A	T366N
c.1097C>T	c.C1097T	T366I
c.1099A>C	c.A1099C	I367L
c.1099A>T	c.A1099T	I367F
c.1101C>G	c.C1101G	I367M
c.1102G>A	c.G1102A	A368T
c.1102G>C	c.G1102C	A368P
c.1103C>G	c.C1103G	A368G
c.1105G>A	c.G1105A	V369I
c.1105G>C	c.G1105C	V369L
c.1105G>T	c.G1105T	V369F
c.1106T>C	c.T1106C	V369A
c.1106T>G	c.T1106G	V369G
c.1108G>A	c.G1108A	A370T
c.1108G>C	c.G1108C	A370P
c.1109C>A	c.C1109A	A370D
c.1109C>G	c.C1109G	A370G
c.1109C>T	c.C1109T	A370V
c.1111T>A	c.T1111A	S371T
c.1112C>G	c.C1112G	S371C
c.1117G>A	c.G1117A	G373S
c.1117G>T	c.G1117T	G373C
c.1118G>C	c.G1118C	G373A
c.1120A>G	c.A1120G	K374E
c.1121A>C	c.A1121C	K374T
c.1121A>G	c.A1121G	K374R
c.1121A>T	c.A1121T	K374I
c.1123G>C	c.G1123C	G375R
c.1124G>A	c.G1124A	G375E
c.1124G>C	c.G1124C	G375A
c.1126G>A	c.G1126A	V376M
c.1126G>C	c.G1126C	V376L
c.1127T>A	c.T1127A	V376E
c.1127T>G	c.T1127G	V376G
c.1129G>A	c.G1129A	A377T
c.1129G>C	c.G1129C	A377P
c.1129G>T	c.G1129T	A377S
c.1130C>G	c.C1130G	A377G
c.1135A>G	c.A1135G	N379D
c.1136A>C	c.A1136C	N379T
c.1136A>T	c.A1136T	N379I
c.1137T>A	c.T1137A	N379K
c.1138C>A	c.C1138A	P380T
c.1138C>G	c.C1138G	P380A
c.1139C>A	c.C1139A	P380H
c.1139C>G	c.C1139G	P380R
c.1139C>T	c.C1139T	P380L

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.1142C>A	c.C1142A	A381D
c.1147T>A	c.T1147A	F383I
c.1148T>A	c.T1148A	F383Y
c.1148T>G	c.T1148G	F383C
c.1150A>T	c.A1150T	I384F
c.1151T>C	c.T1151C	I384T
c.1152C>G	c.C1152G	I384M
c.1153A>G	c.A1153G	T385A
c.1154C>T	c.C1154T	T385I
c.1156C>A	c.C1156A	Q386K
c.1157A>T	c.A1157T	Q386L
c.1158G>C	c.G1158C	Q386H
c.1159C>A	c.C1159A	L387I
c.1159C>T	c.C1159T	L387F
c.1160T>A	c.T1160A	L387H
c.1160T>G	c.T1160G	L387R
c.1162C>A	c.C1162A	L388I
c.1162C>G	c.C1162G	L388V
c.1162C>T	c.C1162T	L388F
c.1163T>A	c.T1163A	L388H
c.1163T>G	c.T1163G	L388R
c.1168G>A	c.G1168A	V390M
c.1171A>C	c.A1171C	K391Q
c.1171A>G	c.A1171G	K391E
c.1172A>C	c.A1172C	K391T
c.1172A>G	c.A1172G	K391R
c.1172A>T	c.A1172T	K391I
c.1173A>T	c.A1173T	K391N
c.1174A>G	c.A1174G	R392G
c.1174A>T	c.A1174T	R392W
c.1175G>A	c.G1175A	R392K
c.1175G>C	c.G1175C	R392T
c.1175G>T	c.G1175T	R392M
c.1177A>C	c.A1177C	K393Q
c.1177A>G	c.A1177G	K393E
c.1178A>C	c.A1178C	K393T
c.1179G>C	c.G1179C	K393N
c.1180C>A	c.C1180A	L394I
c.1181T>A	c.T1181A	L394Q
c.1181T>C	c.T1181C	L394P
c.1181T>G	c.T1181G	L394R
c.1183G>C	c.G1183C	G395R
c.1184G>A	c.G1184A	G395E
c.1184G>C	c.G1184C	G395A
c.1186T>A	c.T1186A	F396I
c.1186T>G	c.T1186G	F396V
c.1187T>G	c.T1187G	F396C
c.1188C>G	c.C1188G	F396L
c.1189T>A	c.T1189A	Y397N
c.1189T>C	c.T1189C	Y397H



**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.1190A>C	c.A1190C	Y397S
c.1190A>G	c.A1190G	Y397C
c.1190A>T	c.A1190T	Y397F
c.1192G>A	c.G1192A	E398K
c.1192G>C	c.G1192C	E398Q
c.1193A>G	c.A1193G	E398G
c.1195T>A	c.T1195A	W399R
c.1195T>G	c.T1195G	W399G
c.1198A>C	c.A1198C	T400P
c.1198A>G	c.A1198G	T400A
c.1198A>T	c.A1198T	T400S
c.1199C>A	c.C1199A	T400N
c.1199C>T	c.C1199T	T400I
c.1201T>A	c.T1201A	S401T
c.1201T>G	c.T1201G	S401A
c.1202_1203insGACTTC	c.1202_1203insGACTTC	p.T400_S401dup
c.1202C>T	c.C1202T	S401L
c.1204A>G	c.A1204G	R402G
c.1204A>T	c.A1204T	R402W
c.1205G>C	c.G1205C	R402T
c.1205G>T	c.G1205T	R402M
c.1206G>C	c.G1206C	R402S
c.1207T>G	c.T1207G	L403V
c.1208T>C	c.T1208C	L403S
c.1209A>T	c.A1209T	L403F
c.1210A>G	c.A1210G	R404G
c.1211G>A	c.G1211A	R404K
c.1211G>C	c.G1211C	R404T
c.1211G>T	c.G1211T	R404I
c.1212A>T	c.A1212T	R404S
c.1213A>G	c.A1213G	S405G
c.1216C>G	c.C1216G	H406D
c.1217A>T	c.A1217T	H406L
c.1218C>G	c.C1218G	H406Q
c.1219A>T	c.A1219T	I407L
c.1220T>C	c.T1220C	I407T
c.1221A>G	c.A1221G	I407M
c.1222A>C	c.A1222C	N408H
c.1222A>G	c.A1222G	N408D
c.1222A>T	c.A1222T	N408Y
c.1223A>C	c.A1223C	N408T
c.1225C>A	c.C1225A	P409T
c.1225C>G	c.C1225G	P409A
c.1225C>T	c.C1225T	P409S
c.1226C>T	c.C1226T	P409L
c.1228A>G	c.A1228G	T410A
c.1228A>T	c.A1228T	T410S
c.1229C>T	c.C1229T	T410I

**Table 2: Galafold (migalastat) amenability table**

Nucleotide change	Nucleotide change	Protein sequence change
c.1231G>A	c.G1231A	G411S
c.1231G>T	c.G1231T	G411C
c.1232G>A	c.G1232A	G411D
c.1232G>C	c.G1232C	G411A
c.1232G>T	c.G1232T	G411V
c.1234A>C	c.A1234C	T412P
c.1234A>G	c.A1234G	T412A
c.1234A>T	c.A1234T	T412S
c.1235C>A	c.C1235A	T412N
c.1235C>T	c.C1235T	T412I
c.1237G>A	c.G1237A	V413I
c.1237G>T	c.G1237T	V413F
c.1238T>G	c.T1238G	V413G
c.1240T>G	c.T1240G	L414V
c.1242G>C	c.G1242C	L414F
c.1243C>A	c.C1243A	L415I
c.1244T>A	c.T1244A	L415H
c.1246C>G	c.C1246G	Q416E
c.1247A>T	c.A1247T	Q416L
c.1248G>C	c.G1248C	Q416H
c.1249C>A	c.C1249A	L417I
c.1252G>A	c.G1252A	E418K
c.1252G>C	c.G1252C	E418Q
c.1253A>C	c.A1253C	E418A
c.1253A>G	c.A1253G	E418G
c.1254A>T	c.A1254T	E418D
c.1255A>G	c.A1255G	N419D
c.1255A>T	c.A1255T	N419Y
c.1256A>C	c.A1256C	N419T
c.1256A>G	c.A1256G	N419S
c.1256A>T	c.A1256T	N419I
c.1258A>C	c.A1258C	T420P
c.1258A>T	c.A1258T	T420S
c.1259C>A	c.C1259A	T420K
c.1259C>G	c.C1259G	T420R
c.1261A>G	c.A1261G	M421V
c.1261A>T	c.A1261T	M421L
c.1262T>A	c.T1262A	M421K
c.1262T>C	c.T1262C	M421T
c.1262T>G	c.T1262G	M421R
c.1263G>C	c.G1263C	M421I
c.1265A>C	c.A1265C	Q422P
c.1267A>T	c.A1267T	M423L
c.1268T>A	c.T1268A	M423K
c.1268T>C	c.T1268C	M423T
c.1269G>C	c.G1269C	M423I
c.1271C>T	c.C1271T	S424L
c.1275A>C	c.A1275C	L425F
c.1279G>A	c.G1279A	D427N
c.1286T>G	c.T1286G	L429R

## Pharmacodynamic effects

Treatment with Galafold in phase 2 pharmacodynamic studies generally resulted in increases in endogenous  $\alpha$ -Gal A activity in WBCs, as well as in skin and kidney for the majority of patients. In patients with amenable mutations, GL-3 levels tended to decrease in urine and in kidney interstitial capillaries.

## Clinical efficacy and safety

The clinical efficacy and safety of Galafold have been evaluated in two phase 3 pivotal clinical studies and two open-label extension (OLE) clinical studies. All patients received the recommended dosage of 123 mg Galafold every other day.

The first phase 3 clinical study (ATTRACT) was a randomised open-label active comparator study that evaluated the efficacy and safety of Galafold compared to enzyme replacement therapy (ERT) (agalsidase beta, agalsidase alfa) in 52 male and female patients with Fabry disease who were receiving ERT prior to clinical study entry and who have amenable mutations (ERT-experienced clinical study). The clinical study was structured in two periods. During the first period (18-months) ERT-experienced patients were randomised to switch from ERT to Galafold or continue with ERT. The second period was an optional 12-month open-label extension in which all subjects received Galafold.

The second phase 3 clinical study (FACETS) was a 6-month randomised double-blind placebo-controlled study (through month 6) with an 18-month open-label period to evaluate the efficacy and safety of Galafold in 50 male and female patients with Fabry disease who were naïve to ERT, or had previously been on ERT and had stopped for at least 6 months and who have amenable mutations (ERT-naïve study).

The first OLE clinical study (AT1001-041) included patients from phase 2 and phase 3 studies and has completed. The mean extent of exposure to the marketed dose of migalastat 123 mg QOD in patients completing study AT1001-041 was 3.57 ( $\pm$ 1.23) years (n=85). The maximum exposure was 5.6 years.

The second OLE clinical study (AT1001-042) included patients that either transferred from OLE study AT1001-041 or directly from phase 3 study ATTRACT. The mean extent of exposure to the marketed dose of Galafold 123 mg QOD in patients completing this study was 32.3 ( $\pm$ 12.3) months (n=84). The maximum exposure was 51.9 months.

## Renal function

In the ERT-experienced clinical study, renal function remained stable for up to 18 months of treatment with Galafold. Mean annualised rate of change in  $eGFR_{CKD-EPI}$  was  $-0.40$  mL/min/1.73 m<sup>2</sup> (95% CI:  $-2.272, 1.478$ ; n=34) in the Galafold group compared to  $-1.03$  mL/min/1.73 m<sup>2</sup> (95% CI:  $-3.636, 1.575$ ; n=18) in the ERT group. The mean annualised rate of change from baseline in  $eGFR_{CKD-EPI}$  in patients treated for 30 months with Galafold was  $-1.72$  mL/min/1.73 m<sup>2</sup> (95% CI:  $-2.653, -0.782$ ; n=31).

In the ERT-naïve clinical study and open-label extension, renal function remained stable for up to 5 years of treatment with Galafold. After an average of 3.4 years of treatment, the mean annualised rate of change in  $eGFR_{CKD-EPI}$  was  $-0.74$  mL/min/1.73 m<sup>2</sup> (95% CI:  $-1.89, 0.40$ ; n=41). No clinically significant differences were observed during the initial 6-month placebo-controlled period.

Data for the annualised rate of change for  $eGFR_{CKD-EPI}$  was pooled for ERT-naïve subjects and ERT-experienced subjects with amenable mutations; the results showed the durability of renal stabilization up to 8.6 years in annualised rate of change. After a mean duration of 5.2 years, ERT-naïve patients

had a mean annualised rate of change from baseline of -1.71 mL/min/1.73 m<sup>2</sup> (CI: -2.83, -0.60; n=47). After a mean duration of 4.3 years, ERT-experienced patients had a mean annualised rate of change from baseline of -1.78 mL/min/1.73 m<sup>2</sup> (CI: -3.76, 0.20; n=49).

### Left ventricular mass index (LVMI)

In the ERT-experienced clinical study, following 18 months of treatment with Galafold there was a statistically significant decrease in LVMI ( $p < 0.05$ ). The baseline values were 95.3 g/m<sup>2</sup> for the Galafold arm and 92.9 g/m<sup>2</sup> for the ERT arm and the mean change from baseline in LVMI at month 18 was -6.6 (95% CI: -11.0, -2.1; n=31) for Galafold and -2.0 (95% CI: -11.0, 7.0; n=13) for ERT. The change from baseline to month 18 in LVMI (g/m<sup>2</sup>) in patients with left ventricular hypertrophy (females with baseline LVMI >95 g/m<sup>2</sup> and males with baseline LVMI >115 g/m<sup>2</sup>) was -8.4 (95% CI: -15.7, 2.6; n=13) for Galafold and 4.5 (95% CI: -10.7, 18.4; n=5) for ERT. After 30 months treatment with Galafold, the mean change from baseline in LVMI was -3.8 (95% CI: -8.9, 1.3; n=28) and the mean change from baseline in LVMI in patients with left ventricular hypertrophy at baseline was -10.0 (95% CI: -16.6, -3.3; n=10).

In the ERT-naïve clinical study, Galafold resulted in a statistically significant decrease in LVMI ( $p < 0.05$ ); the mean change from baseline in LVMI at month 18 to 24 was -7.7 (95% CI: -15.4, -0.01; n=27). After follow-up in the OLE, the mean change from baseline in LVMI at month 36 was -8.3 (95% CI: -17.1, 0.4; n=25) and at month 48 was -9.1 (95% CI: -20.3, 2.0; n=18). The mean change from baseline in LVMI at month 18 to 24 in patients with left ventricular hypertrophy at baseline (females with baseline LVMI >95 g/m<sup>2</sup> or males with baseline LVMI >115 g/m<sup>2</sup>) was -18.6 (95% CI: -38.2, 1.0; n=8). After follow-up in the OLE, the mean change from baseline in LVMI at month 36 in patients with left ventricular hypertrophy at baseline was -30.0 (95% CI: -57.9, -2.2; n=4) and at month 48 was -33.1 (CI: -60.9, -5.4; n=4). No clinically significant differences in LVMI were observed during the initial 6-month placebo-controlled period.

In the ERT-experienced and ERT-naïve clinical studies, after follow up in OLE clinical study AT1001-042, the mean change in LVMI from AT1001-042 baseline was 1.2 g/m<sup>2</sup> (95% CI: -5.3, 7.7; n=15) and -5.6 g/m<sup>2</sup> (95% CI: -28.5, 17.2; n=4) respectively, for patients treated with Galafold for an average of 2.4 and 2.9 years (up to 4.0 and 4.3 years, respectively).

### Disease substrate

In the ERT-experienced clinical study, plasma lyso-Gb<sub>3</sub> levels slightly increased but remained low in patients with amenable mutations treated with Galafold for the 30-month duration of the study. Plasma lyso-Gb<sub>3</sub> levels also remained low in patients on ERT for up to 18 months.

In the ERT-naïve clinical study, Galafold showed statistically significant reductions in plasma lyso-Gb<sub>3</sub> concentrations and kidney interstitial capillary GL-3 inclusions in patients with amenable mutations. Patients randomised to Galafold in Stage 1 demonstrated statistically significant greater reduction ( $\pm$ SEM) in mean interstitial capillary GL-3 deposition ( $-0.25 \pm 0.10$ ; -39%) at month 6 compared to placebo ( $+0.07 \pm 0.13$ ; +14%) ( $p = 0.008$ ). Patients randomised to placebo in Stage 1 and switched to Galafold at month 6 (Stage 2) also demonstrated statistically significant decreases in interstitial capillary GL-3 inclusions at month 12 ( $-0.33 \pm 0.15$ ; -58%) ( $p = 0.014$ ). Qualitative reductions in GL-3 levels were observed in multiple renal cell types: podocytes, mesangial cells, and glomerular endothelial cells, respectively, over 12 months of treatment with Galafold.

### Composite clinical outcomes

In the ERT-experienced clinical study, an analysis of a composite clinical outcome composed of renal, cardiac, and cerebrovascular events, or death, showed that the frequency of events observed in the Galafold treatment group was 29% compared to 44% in the ERT group over 18 months. The

frequency of events in patients treated with Galafold over 30 months (32%) was similar to the 18-month period.

#### Patient-reported outcome - gastrointestinal symptoms rating scale

In the ERT-naïve clinical study, analyses of the Gastrointestinal Symptoms Rating Scale demonstrated that treatment with Galafold was associated with statistically significant ( $p < 0.05$ ) improvements versus placebo from baseline to month 6 in the diarrhoea domain, and in the reflux domain for patients with symptoms at baseline. During the open-label extension, statistically significant ( $p < 0.05$ ) improvements from baseline were observed in the diarrhoea and indigestion domains, with a trend of improvement in the constipation domain.

#### Paediatric population

In Study AT1001-020, a 1-year, Phase 3b, open-label, uncontrolled, multicentre study, the safety, PK, pharmacodynamic (PD), and efficacy of migalastat treatment was evaluated in 21 adolescent subjects (12 to  $< 18$  years of age and weighing  $\geq 45$  kg) with Fabry disease and who have amenable mutations of the gene encoding  $\alpha$ -galactosidase A (*GLA*). Subjects were either naïve to enzyme replacement therapy (ERT) or had stopped ERT at least 14 days before screening. The mean number of years since diagnosis of Fabry disease was 10.2 ( $\pm 4.12$ ) years.

At 1 year, the efficacy results in adolescents on the same dosing regimen as adults were consistent in renal, cardiac, and pharmacodynamic results as well as responses to patient-reported outcomes. The overall mean (SD) change from baseline in eGFR was -1.6 (15.4) mL/min/1.73 m<sup>2</sup> (n=19). The overall mean (SD) change from baseline for LVMi was -3.9 (13.5) g/m<sup>2</sup> (n=18). LVMi decreased in 10 subjects and increased in 8 subjects, but all subjects remained within normal limits at 12 months. Baseline plasma lyso-Gb<sub>3</sub> was 12.00 ng/mL and the overall mean (SD) change from baseline in plasma lyso-Gb<sub>3</sub> was -0.06 (32.9) (n=19). A reduction in plasma lyso-Gb<sub>3</sub> from baseline was observed in ERT-naïve subjects (median -2.23 ng/ml, n=9) and levels remained generally stable in ERT-experienced subjects (median 0.54 ng/ml, n=10). There were no notable changes in patient reported outcomes.

The European Medicines Agency has deferred the obligation to submit the results of studies with Galafold in one or more subsets of the paediatric population in the treatment of Fabry disease (see section 4.2 for information on paediatric use).

## **5.2 Pharmacokinetic properties**

### Absorption

The absolute bioavailability (AUC) for a single oral 150 mg migalastat hydrochloride dose or a single 2-hour 150 mg intravenous infusion was approximately 75%. Following a single oral dose of 150 mg migalastat hydrochloride solution, the time to peak plasma concentration was approximately 3 hours. Plasma migalastat exposure (AUC<sub>0-∞</sub>) and C<sub>max</sub> demonstrated dose-proportional increases at migalastat hydrochloride oral doses from 50 mg to 1,250 mg in adults.

Migalastat administered with a high-fat meal, or 1 hour before a high-fat or light meal, or 1 hour after a light meal, resulted in significant reductions of 37% to 42% in mean total migalastat exposure (AUC<sub>0-∞</sub>) and reductions of 15% to 40% in mean peak migalastat exposure (C<sub>max</sub>) compared with the fasting state (see section 4.2).

### Distribution

In healthy volunteers, the volume of distribution (V<sub>z</sub>/F) of migalastat following ascending single oral doses (25 to 675 mg migalastat hydrochloride) ranged from 77 to 133 L, indicating it is well distributed into tissues and greater than total body water (42 litres). There was no detectable plasma

protein binding following administration of [<sup>14</sup>C]-migalastat hydrochloride in the concentration range between 1 and 100 µM.

### Biotransformation

Based upon *in vivo* data, migalastat is a substrate for UGT, being a minor elimination pathway. Migalastat is not a substrate for P-glycoprotein (P-gP) *in vitro* and it is considered unlikely that migalastat would be subject to drug-drug interactions with cytochrome P450s. A pharmacokinetic study in healthy male volunteers with 150 mg [<sup>14</sup>C]-migalastat hydrochloride revealed that 99% of the radiolabelled dose recovered in plasma was comprised of unchanged migalastat (77%) and 3 dehydrogenated O-glucuronide conjugated metabolites, M1 to M3 (13%). Approximately 9% of the total radioactivity was unassigned.

### Elimination

A pharmacokinetic study in healthy male volunteers with 150 mg [<sup>14</sup>C]-migalastat hydrochloride revealed that approximately 77% of the radiolabeled dose was recovered in urine of which 55% of was excreted as unchanged migalastat and 4% as combined metabolites M1, M2 and M3. Approximately 5% of the total sample radioactivity was unassigned components. Approximately 20% of the total radiolabeled dose was excreted in faeces, with unchanged migalastat being the only measured component.

Following ascending single oral doses (25 to 675 mg migalastat hydrochloride), no trends were found for clearance, CL/F. At the 150 mg dose, CL/F was approximately 11 to 14 L/hr. Following administration of the same doses, the mean elimination half-life ( $t_{1/2}$ ) ranged from approximately 3 to 5 hours.

### Special populations

#### *Patients with renal impairment*

Galafold has not been studied in patients with Fabry disease who have a GFR less than 30 mL/min/1.73 m<sup>2</sup>. In a single dose study with Galafold in non-Fabry subjects with varying degrees of renal insufficiency, exposures were increased by 4.3-fold in subjects with severe renal impairment (GFR <30 mL/min/1.73 m<sup>2</sup>).

#### *Patients with hepatic impairment*

No studies have been carried out in subjects with impaired hepatic function. From the metabolism and excretion pathways, it is not expected that a decreased hepatic function may affect the pharmacokinetics of migalastat.

#### *Elderly (>65 years)*

Clinical studies of Galafold included small number of patients aged 65 and over. The effect of age was evaluated in a population pharmacokinetic analysis on plasma migalastat clearance in the ERT-naïve study population. The difference in clearance between Fabry patients ≥ 65 years and those < 65 years was 20%, which was not considered clinically significant.

#### *Paediatric population*

The pharmacokinetics of migalastat were characterised in 20 adolescent subjects (12 to < 18 years and weighing ≥45 kg) with Fabry disease who received the same dosage regimen as adults (123 mg migalastat capsule every other day) in an open label phase 3b trial (AT1001-020).

Assessment of bioequivalence of exposure was simulated in adolescent subjects (12 to < 18 years) weighing  $\geq 45$  kg and receiving migalastat 123 mg once every other day compared to adults receiving the same dosing regimen. Model derived AUC<sub>tau</sub> in adolescent subjects (12 to < 18 years) were similar to adult exposures.

### Gender

The pharmacokinetic characteristics of migalastat were not significantly different between females and males in either healthy volunteers or in patients with Fabry disease.

### **5.3 Preclinical safety data**

Non-clinical studies suggest no specific hazard for humans on the basis of single-and repeat-dose studies, with the exception of transient and fully reversible infertility in male rats associated with migalastat treatment. The infertility associated with migalastat treatment was reported at clinically relevant exposures. Complete reversibility was seen after 4 weeks off-dose. Similar findings have been noted pre-clinically following treatment with other iminosugars. In the rabbit embryo-foetal toxicity study, findings including embryo-foetal death, a reduction in mean foetal weight, retarded ossification, and slightly increased incidences of minor skeletal abnormalities were observed only at doses associated with maternal toxicity.

In a rat 104-week carcinogenicity study, there was an increased incidence of pancreatic islet cell adenomas in males at a dose level 19-fold higher than the exposure (AUC) at the clinically efficacious dose. This is a common spontaneous tumour in *ad libitum*-fed male rats. In the absence of similar findings in females, no findings in the genotoxicity battery or in the carcinogenicity study with Tg.rasH2 mice, and no pre-neoplastic pancreatic findings in the rodents or monkeys, this observation in male rats is not considered related to treatment and its relevance to humans is unknown.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### Capsule contents

Pregelatinised starch (maize)  
Magnesium stearate

#### Capsule shell

Gelatin  
Titanium dioxide (E171)  
Indigo carmine (E132)

#### Printing ink

Shellac  
Black iron oxide  
Potassium hydroxide

### **6.2 Incompatibilities**

Not applicable.

### **6.3 Shelf life**

4 years

### **6.4 Special precautions for storage**

This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.

### **6.5 Nature and contents of container**

PVC / PCTFE / PVC/Al blister.  
Pack size of 14 capsules.

### **6.6 Special precautions for disposal**

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Amicus Therapeutics Europe Limited  
Block 1, Blanchardstown Corporate Park  
Ballycoolin Road  
Blanchardstown, Dublin  
D15 AKK1  
Ireland  
Tel: +353 (0) 1 588 0836  
Fax: +353 (0) 1 588 6851  
e-mail: info@amicusrx.co.uk

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/15/1082/001

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date: of first authorisation: 26 May 2016

Date of latest renewal: 11 February 2021

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.



## **ANNEX II**

- A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

## **A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

### Name and address of the manufacturer responsible for batch release

Almac Pharma Services (Ireland) Limited  
Finnabair Industrial Estate  
Dundalk, Co. Louth  
A91 P9KD  
Ireland

## **B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## **C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic safety update reports (PSURs)**

The requirements for submission of PSURs for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## **D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk management plan (RMP)**

The marketing authorisation holder shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

## PARTICULARS TO APPEAR ON THE OUTER PACKAGING

### OUTER CARTON

#### 1. NAME OF THE MEDICINAL PRODUCT

Galafold 123 mg hard capsules  
migalastat

#### 2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat.

#### 3. LIST OF EXCIPIENTS

#### 4. PHARMACEUTICAL FORM AND CONTENTS

hard capsule

14 hard capsules

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Do not eat food at least 2 hours before and 2 hours after taking your medicine to give a minimum 4 hours fast. Take at the same time each day.


Swallow the capsule whole. Do not cut, crush, or chew the capsule.


Read the package leaflet before use.

Oral use.

Take Galafold capsule every other day and punch out the perforated circle on the blister sleeve on the days you are not taking Galafold.

#### How to Remove a Capsule



1. PRESS and hold purple tab, and PULL out card on the right (Figure 1). Unfold the card.
2. Turn the card over showing the back side of the card. BEND card (Figure 2) to help raise perforations.
3. REMOVE the oval perforated  cardboard (Figure 3).
4. Turn the card over showing the front side of the card. Push capsule out (Figure 4).

To access the package leaflet, scan the code below.  
*QR code to be included* + [www.galafoldsmpc.co.uk](http://www.galafoldsmpc.co.uk)

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

EXP

**9. SPECIAL STORAGE CONDITIONS**

Store in the original package in order to protect from moisture.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Amicus Therapeutics Europe Limited  
Block 1, Blanchardstown Corporate Park  
Ballycoolin Road  
Blanchardstown, Dublin  
D15 AKK1  
Ireland

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/15/1082/001

**13. BATCH NUMBER**

Lot

**14. GENERAL CLASSIFICATION FOR SUPPLY**

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

galafold 123 mg hard capsules

**17. UNIQUE IDENTIFIER – 2D BARCODE**

2D barcode carrying the unique identifier included.

**18. UNIQUE IDENTIFIER - HUMAN READABLE DATA**

PC  
SN  
NN

**MINIMUM PARTICULARS TO APPEAR ON INTERMEDIATE PACKAGING**

**BLISTER SLEEVE**

**1. NAME OF THE MEDICINAL PRODUCT**

Galafold 123 mg hard capsules  
migalastat

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

Amicus Therapeutics Europe Limited

**3. EXPIRY DATE**

EXP

**4. BATCH NUMBER**

Lot

**5. OTHER**

See package leaflet for further instructions.

Punch out the perforated circles on days you are not taking Galafold.

Galafold is to be taken every other day.

Starting date:



**MINIMUM PARTICULARS TO APPEAR ON INTERMEDIATE PACKAGING**

**BLISTER FOIL**

**1. NAME OF THE MEDICINAL PRODUCT**

**2. NAME OF THE MARKETING AUTHORISATION HOLDER**

**3. EXPIRY DATE**

**4. BATCH NUMBER**

Lot

**5. OTHER**

**B. PACKAGE LEAFLET**

## Package leaflet: Information for the patient

### Galafold 123 mg hard capsules migalastat

**Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor, pharmacist, or nurse.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet

1. What Galafold is and what it is used for
2. What you need to know before you take Galafold
3. How to take Galafold
4. Possible side effects
5. How to store Galafold
6. Contents of the pack and other information

#### 1. What Galafold is and what it is used for

Galafold contains the active substance migalastat.

This medicine is used for the long-term treatment of Fabry disease in adults and adolescents aged 12 years and older who have certain genetic mutations (changes).

Fabry disease is caused by the lack of or a faulty enzyme called alpha-galactosidase A ( $\alpha$ -Gal A). Depending upon the kind of mutation (change) in the gene that produces  $\alpha$ -Gal A, the enzyme does not work properly or is completely absent. This enzyme defect leads to abnormal deposits of a fatty substance known as globotriaosylceramide (GL-3) in kidneys, heart, and other organs, leading to the symptoms of Fabry disease.

This medicine works by stabilising the enzyme that your body produces naturally, so that it can work better to reduce the amount of GL-3 that has accumulated in your cells and tissues.

#### 2. What you need to know before you take Galafold

##### Do not take Galafold if you:

- are allergic to migalastat or any of the other ingredients of this medicine (listed in section 6).

##### Warnings and precautions

123 mg migalastat capsules are not for children ( $\geq 12$  years) weighing less than 45 kg.

Talk to your doctor before taking Galafold if you are currently taking enzyme replacement therapy. You should not take Galafold if you are also receiving enzyme replacement therapy.

Your doctor will monitor your condition and whether your medicine is working every 6 months while you are taking Galafold. If your condition worsens, your doctor may evaluate you further or may discontinue your treatment with Galafold.

Talk to your doctor before taking Galafold if you have severely reduced kidney function as Galafold is not recommended for use in patients with severe renal insufficiency (GFR less than 30 mL/min/1.73m<sup>2</sup>).

## **Children**

### *Children <12 years*

This medicine has not been studied in children under the age of 12; therefore, the safety and efficacy in this age group has not been established.

## **Other medicines and Galafold**

Tell your doctor, pharmacist or nurse if you are taking, have recently taken, or might take any other medicines.

## **Pregnancy, breast-feeding, and fertility**

### *Pregnancy*

There is very limited experience with the use of this medicine in pregnant women. Galafold is not recommended during pregnancy. If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.

Women who could become pregnant should use effective birth control while taking Galafold.

### *Breast-feeding*

Do not take this medicine if you are breast-feeding, until you have spoken with your doctor, pharmacist, or nurse. It is not yet known whether this medicine passes into breast milk. Your doctor will decide whether you need to stop breast-feeding or temporarily stop your medicine, considering the benefit of breast-feeding to the baby and the benefit of Galafold to the mother.

### *Fertility in men*

It is not yet known if this medicine affects fertility in men. The effects of Galafold on fertility in humans have not been studied.

### *Fertility in women*

It is not yet known if this medicine affects fertility in women.

If you are planning to have a baby, ask your doctor, pharmacist, or nurse for advice.

## **Driving and using machines**

It is unlikely that this medicine will affect your ability to drive and use machines.

## **3. How to take Galafold**


Always take this medicine exactly as your doctor, pharmacist, or nurse has told you. Check with your doctor, pharmacist, or nurse if you are not sure.

Take one capsule every other day at the same time of the day. Do not take Galafold on two consecutive days.

Do not eat food at least 2 hours before and 2 hours after taking your medicine. This minimum 4 hours fast around taking your medicine is needed to allow your medicine to be fully absorbed. Clear liquids, including carbonated drinks, can be consumed during this period.


Swallow the capsule whole. Do not cut, crush, or chew the capsule.

Figure A




Step 1: Remove the adhesive seal holding the cover.  
Lift the cover of your Galafold carton (see Figure A).

Figure B – Opened carton




Step 2: Press and continue holding down the purple tab with your thumb at the **left** side of the carton (see Figure B), and continue to Step 3.

Figure C



Step 3: Now **GRASP the tab** on the **right side** where it says “PULL OUT HERE” and pull out the folded blister card (see Figure C).

Figure D – Front of the blister card



Step 4: Unfold the blister card (see Figure D).

### Taking Galafold Capsule:

One Galafold blister card = 14 hard capsules = 28 days of treatment with Galafold, and 14 white cardboard circles.

The white cardboard circles are to remind you to take Galafold every **other** day.

The arrow directs the patient to begin the next 2 weeks of treatment.

Figure E – Front of the blister card






Figure F – Front of the blister card



Step 5: On your first day of taking this medicine from a new blister card, record the date on the blister card (see Figure F).

Figure G – Back of the blister card




Step 6: TURN the card OVER showing the back of the card.

LOCATE capsule to remove.  
BEND the card as shown  
(see Figure G).

Note: Bending the card helps raise the oval perforated cardboard.


Figure H – Back of the blister card



Step 7: REMOVE the oval perforated cardboard (see Figure H).

Note: After removing the cardboard, the white backing of the foil may be present, which is ok.


Figure I – Front of the blister card



Step 8: TURN the card OVER showing the front of the card.

PUSH the capsule out (see Figure I).

Figure J – Front of the blister card



Step 9: On the next day, move to the perforated white cardboard circle on the top row labelled Day 2.

Press down on the white cardboard circle removing it (see Figure J).


Note: Removing this white circle will help you remember which day you do not take the medicine.

Take 1 Galafold capsule every **other** day.

Close package and store after each use.

After Day 2, move to Day 3 on the blister card.  
Alternate daily between taking the capsule and pushing out the perforated white cardboard circles, up to and including day 28.

Figure K – Front of the unfolded blister card



**If you take more Galafold than you should**

If you take more capsules than you should, then you should stop taking the medicine and contact your doctor. You may get a headache and feel dizzy.

**If you forget to take Galafold**

If you forget to take your capsule at the usual time but remember later, you can take the capsule only if it is within 12 hours of your normal dosing time. If more than 12 hours has passed, you should resume taking Galafold at the next planned dosing day and time according to your every other day dosing schedule. Do not take two capsules to make up for your missed dose.

**If you stop taking Galafold**

Do not stop taking this medicine without talking to your doctor.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

**4. Possible side effects**

Like all medicines, this medicine can cause side effects, although not everybody gets them.

**Very common:** may affect more than 1 in 10 people

- Headache



**Common:** may affect up to 1 in 10 people

- Palpitations (the feeling of a pounding heart)
- Sensation of spinning (vertigo)
- Diarrhoea
- Feeling sick (nausea)
- Stomachache
- Constipation
- Dry mouth
- Sudden need to defecate
- Indigestion (dyspepsia)
- Tiredness
- Raised levels of creatine phosphokinase in blood tests
- Weight gain
- Muscle spasms
- Muscle pain (myalgia)
- Painful stiff neck (torticollis)
- Tingling in extremities (paraesthesia)
- Dizziness
- Reduced sense of touch or sensation (hypoesthesia)
- Depression
- Protein in the urine (proteinuria)
- Shortness of breath (dyspnoea)
- Nose bleed (epistaxis)
- Rash
- Persistent itch (pruritus)
- Pain

## Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## 5. How to store Galafold

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date, which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicinal product does not require any special temperature storage conditions. Store in the original package in order to protect from moisture.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

## 6. Contents of the pack and other information

### What Galafold contains

- The active substance is migalastat. Each capsule contains migalastat hydrochloride equivalent to 123 mg migalastat
- The other ingredients are:  
Capsule contents: Pregelatinised starch (maize) and magnesium stearate  
Capsule shell: Gelatin, titanium dioxide (E171), and indigo carmine (E132)  
Printing ink: Shellac, black iron oxide, and potassium hydroxide

### What Galafold looks like and contents of the pack

Opaque, blue, and white hard capsules, marked with “A1001” in black ink, size 2 hard capsule (6.4 x 18.0 mm) containing white to pale brown powder.

Galafold is available in a blister pack containing 14 capsules.

**Marketing Authorisation Holder**

Amicus Therapeutics Europe Limited  
Block 1, Blanchardstown Corporate Park  
Ballycoolin Road  
Blanchardstown, Dublin  
D15 AKK1  
Ireland  
Tel: +353 (0) 1 588 0836  
Fax: +353 (0) 1 588 6851  
e-mail: info@amicusrx.co.uk

**Manufacturer**

Almac Pharma Services (Ireland) Limited  
Finnabair Industrial Estate  
Dundalk, Co. Louth  
A91 P9KD  
Ireland

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder (if you cannot reach your Amicus representative by phone please contact via the e-mail address listed below):

**België/Belgique/Belgien**

Amicus Therapeutics Europe Limited  
Tél/Tel: (+32) 0800 89172  
e-mail: MedInfo@amicusrx.com

**България**

Amicus Therapeutics Europe Limited  
Тел.: (+359) 00800 111 3214  
имейл: MedInfo@amicusrx.com

**Česká republika**

Amicus Therapeutics Europe Limited  
Tel.: (+420) 800 142 207  
e-mail: MedInfo@amicusrx.com

**Danmark**

Amicus Therapeutics Europe Limited  
Tlf.: (+45) 80 253 262  
e-mail: MedInfo@amicusrx.com

**Deutschland**

Amicus Therapeutics GmbH  
Tel: (+49) 0800 000 2038  
E-Mail: MedInfo@amicusrx.com

**Eesti**

Amicus Therapeutics Europe Limited  
Tel: (+372) 800 0111 911  
e-post: MedInfo@amicusrx.com

**Lietuva**

Amicus Therapeutics Europe Limited  
Tel: (+370) 8800 33167  
El. paštas: MedInfo@amicusrx.com

**Luxembourg/Luxemburg**

Amicus Therapeutics Europe Limited  
Tél/Tel: (+352) 800 27003  
e-mail: MedInfo@amicusrx.com

**Magyarország**

Amicus Therapeutics Europe Limited  
Tel.: (+36) 06 800 21202  
e-mail: MedInfo@amicusrx.com

**Malta**

Amicus Therapeutics Europe Limited  
Tel: (+356) 800 62674  
e-mail: MedInfo@amicusrx.com

**Nederland**

Amicus Therapeutics BV  
Tel: (+31) 0800 022 8399  
e-mail: MedInfo@amicusrx.com

**Norge**

Amicus Therapeutics Europe Limited  
Tlf: (+47) 800 13837  
e-post: MedInfo@amicusrx.com

**Ελλάδα**

Amicus Therapeutics Europe Limited  
Τηλ: (+30) 00800 126 169  
e-mail: MedInfo@amicusrx.com

**España**

Amicus Therapeutics S.L.U.  
Tel: (+34) 900 941 616  
e-mail: MedInfo@amicusrx.com

**France**

Amicus Therapeutics SAS  
Tél: (+33) 0 800 906 788  
e-mail: MedInfo@amicusrx.com

**Hrvatska**

Amicus Therapeutics Europe Limited  
Tel: (+358) 0800 222 452  
e-pošta: MedInfo@amicusrx.com

**Ireland**

Amicus Therapeutics Europe Limited  
Tel: (+353) 1800 936 230  
e-mail: MedInfo@amicusrx.com

**Ísland**

Amicus Therapeutics Europe Limited  
Sími: (+354) 800 7634  
Netfang: MedInfo@amicusrx.com

**Italia**

Amicus Therapeutics S.r.l.  
Tel: (+39) 800 795 572  
e-mail: MedInfo@amicusrx.com

**Κύπρος**

Amicus Therapeutics Europe Limited  
Τηλ: (+357) 800 97595  
e-mail: MedInfo@amicusrx.com

**Latvija**

Amicus Therapeutics Europe Limited  
Tel: (+371) 800 05391  
e-pasts: MedInfo@amicusrx.com

**Österreich**

Amicus Therapeutics Europe Limited  
Tel: (+43) 0800 909 639  
E-Mail: MedInfo@amicusrx.com

**Polska**

Amicus Therapeutics Europe Limited  
Tel.: (+48) 0080 012 15475  
e-mail: MedInfo@amicusrx.com

**Portugal**

Amicus Therapeutics Europe Limited  
Tel: (+351) 800 812 531  
e-mail: MedInfo@amicusrx.com

**România**

Amicus Therapeutics Europe Limited  
Tel.: (+40) 0808 034 288  
e-mail: MedInfo@amicusrx.com

**Slovenija**

Amicus Therapeutics Europe Limited  
Tel.: (+386) 0800 81794  
e-pošta: MedInfo@amicusrx.com

**Slovenská republika**

Amicus Therapeutics Europe Limited  
Tel: (+421) 0800 002 437  
e-mail: MedInfo@amicusrx.com

**Suomi/Finland**

Amicus Therapeutics Europe Limited  
Puh/Tel: (+358) 0800 917 780  
sähköposti/e-mail: MedInfo@amicusrx.com

**Sverige**

Amicus Therapeutics Europe Limited  
Tfn: (+46) 020 795 493  
e-post: MedInfo@amicusrx.com

**United Kingdom (Northern Ireland)**

Amicus Therapeutics, UK Limited  
Tel: (+44) 08 0823 46864  
e-mail: MedInfo@amicusrx.com

**This leaflet was last revised in**

**Other sources of information**

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>. There are also links to other websites about rare diseases and treatments.